JPWO2007126042A1 - 2−アミノブタノール化合物及びその医薬用途 - Google Patents
2−アミノブタノール化合物及びその医薬用途 Download PDFInfo
- Publication number
- JPWO2007126042A1 JPWO2007126042A1 JP2008513283A JP2008513283A JPWO2007126042A1 JP WO2007126042 A1 JPWO2007126042 A1 JP WO2007126042A1 JP 2008513283 A JP2008513283 A JP 2008513283A JP 2008513283 A JP2008513283 A JP 2008513283A JP WO2007126042 A1 JPWO2007126042 A1 JP WO2007126042A1
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- halogen atom
- added
- compound
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2-Aminobutanol compound Chemical class 0.000 title claims abstract description 154
- 150000001875 compounds Chemical class 0.000 claims abstract description 186
- 125000005843 halogen group Chemical group 0.000 claims abstract description 78
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 55
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 51
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 45
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 41
- 239000002253 acid Substances 0.000 claims abstract description 35
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 32
- 125000002252 acyl group Chemical group 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 125000000732 arylene group Chemical group 0.000 claims abstract description 19
- 239000012453 solvate Substances 0.000 claims abstract description 19
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 18
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 13
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 125000004430 oxygen atom Chemical group O* 0.000 claims abstract description 10
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims abstract description 8
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims abstract description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 6
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 110
- 125000006239 protecting group Chemical group 0.000 claims description 36
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 26
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 15
- VYFZAYULNQOSQP-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-(4-methylphenyl)sulfanylphenyl]phenyl]ethyl]propane-1,3-diol Chemical compound C1=CC(C)=CC=C1SC1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)C(F)=C1 VYFZAYULNQOSQP-UHFFFAOYSA-N 0.000 claims description 13
- 125000005549 heteroarylene group Chemical group 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000010511 deprotection reaction Methods 0.000 claims description 7
- 150000004677 hydrates Chemical class 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 238000010322 bone marrow transplantation Methods 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 230000001629 suppression Effects 0.000 claims description 4
- 210000001519 tissue Anatomy 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 11
- 208000006218 bradycardia Diseases 0.000 abstract description 6
- 230000036471 bradycardia Effects 0.000 abstract description 6
- 230000009471 action Effects 0.000 abstract description 5
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 3
- 125000005842 heteroatom Chemical group 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 297
- 239000000203 mixture Substances 0.000 description 154
- 239000002904 solvent Substances 0.000 description 148
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 140
- 238000006243 chemical reaction Methods 0.000 description 129
- 239000000243 solution Substances 0.000 description 124
- 239000013078 crystal Substances 0.000 description 118
- 230000002829 reductive effect Effects 0.000 description 110
- 238000005160 1H NMR spectroscopy Methods 0.000 description 95
- 239000011541 reaction mixture Substances 0.000 description 95
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 92
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 81
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 72
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 72
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 71
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 238000010898 silica gel chromatography Methods 0.000 description 64
- 238000003786 synthesis reaction Methods 0.000 description 59
- 230000015572 biosynthetic process Effects 0.000 description 58
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 57
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 238000010992 reflux Methods 0.000 description 47
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 46
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 44
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 42
- 238000001914 filtration Methods 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 39
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 37
- 239000000047 product Substances 0.000 description 37
- LNAMMBFJMYMQTO-FNEBRGMMSA-N chloroform;(1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].ClC(Cl)Cl.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 LNAMMBFJMYMQTO-FNEBRGMMSA-N 0.000 description 36
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 34
- 238000000034 method Methods 0.000 description 32
- 238000001816 cooling Methods 0.000 description 29
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 28
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 27
- 238000000605 extraction Methods 0.000 description 27
- 239000012299 nitrogen atmosphere Substances 0.000 description 25
- 239000012044 organic layer Substances 0.000 description 23
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 23
- 235000017557 sodium bicarbonate Nutrition 0.000 description 23
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 22
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000001953 recrystallisation Methods 0.000 description 18
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 17
- KSMXJBMNDAXDEN-UHFFFAOYSA-N n-[5-[2-[4-(4-bromo-2-fluorophenyl)phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C=1C=C(C=2C(=CC(Br)=CC=2)F)C=CC=1CCC1(NC(=O)C)COC(C)(C)OC1 KSMXJBMNDAXDEN-UHFFFAOYSA-N 0.000 description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
- 239000012046 mixed solvent Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 238000005406 washing Methods 0.000 description 16
- 238000001035 drying Methods 0.000 description 15
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 238000002953 preparative HPLC Methods 0.000 description 14
- 125000003277 amino group Chemical group 0.000 description 13
- 239000012267 brine Substances 0.000 description 13
- 239000003054 catalyst Substances 0.000 description 13
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 239000011259 mixed solution Substances 0.000 description 13
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 13
- 125000001424 substituent group Chemical group 0.000 description 13
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 239000012230 colorless oil Substances 0.000 description 12
- 210000002216 heart Anatomy 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 11
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 229910052731 fluorine Inorganic materials 0.000 description 10
- 125000001153 fluoro group Chemical group F* 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 10
- 239000002798 polar solvent Substances 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 9
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 9
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- MYIFLDFUXIHOCJ-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-(3-phenylmethoxyphenyl)sulfanylphenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1SC1=CC=CC(OCC=2C=CC=CC=2)=C1 MYIFLDFUXIHOCJ-UHFFFAOYSA-N 0.000 description 8
- WLHCBQAPPJAULW-UHFFFAOYSA-N 4-methylbenzenethiol Chemical compound CC1=CC=C(S)C=C1 WLHCBQAPPJAULW-UHFFFAOYSA-N 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 7
- 230000003213 activating effect Effects 0.000 description 7
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 7
- 235000011056 potassium acetate Nutrition 0.000 description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 description 7
- 238000000926 separation method Methods 0.000 description 7
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 6
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 6
- 239000004215 Carbon black (E152) Substances 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 230000001476 alcoholic effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 229930195733 hydrocarbon Natural products 0.000 description 6
- 150000002430 hydrocarbons Chemical class 0.000 description 6
- 150000007529 inorganic bases Chemical class 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000007800 oxidant agent Substances 0.000 description 6
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 6
- 150000008300 phosphoramidites Chemical class 0.000 description 6
- 230000000865 phosphorylative effect Effects 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 6
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-Oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 5
- SQKQPJOTLBXORD-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-(4-methylphenoxy)phenyl]phenyl]ethyl]propane-1,3-diol Chemical compound C1=CC(C)=CC=C1OC1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)C(F)=C1 SQKQPJOTLBXORD-UHFFFAOYSA-N 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 5
- SPQGDOFAPBNPMQ-UHFFFAOYSA-L [B+3].[B+3].CC(C)(C)CC(O)C([O-])=O.CC(C)(C)CC(O)C([O-])=O Chemical compound [B+3].[B+3].CC(C)(C)CC(O)C([O-])=O.CC(C)(C)CC(O)C([O-])=O SPQGDOFAPBNPMQ-UHFFFAOYSA-L 0.000 description 5
- 239000001110 calcium chloride Substances 0.000 description 5
- 229910001628 calcium chloride Inorganic materials 0.000 description 5
- 238000006482 condensation reaction Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- SWZTYAVBMYWFGS-UHFFFAOYSA-N fingolimod hydrochloride Chemical compound Cl.CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 SWZTYAVBMYWFGS-UHFFFAOYSA-N 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- YGFLCNPXEPDANQ-UHFFFAOYSA-N n-[bis[(2-methylpropan-2-yl)oxy]phosphanyl]-n-propan-2-ylpropan-2-amine Chemical compound CC(C)N(C(C)C)P(OC(C)(C)C)OC(C)(C)C YGFLCNPXEPDANQ-UHFFFAOYSA-N 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- VUYVXCJTTQJVKJ-UHFFFAOYSA-L palladium(2+);tricyclohexylphosphane;dichloride Chemical compound Cl[Pd]Cl.C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 VUYVXCJTTQJVKJ-UHFFFAOYSA-L 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- HPDBQVCZDFTUOI-UHFFFAOYSA-N 1-bromo-4-(2-iodoethyl)benzene Chemical compound BrC1=CC=C(CCI)C=C1 HPDBQVCZDFTUOI-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- IYHOZKFNCBUEEM-UHFFFAOYSA-N 2-amino-2-[2-[2-chloro-4-[2-fluoro-4-(4-methylphenyl)sulfanylphenyl]phenyl]ethyl]propane-1,3-diol Chemical compound C1=CC(C)=CC=C1SC1=CC=C(C=2C=C(Cl)C(CCC(N)(CO)CO)=CC=2)C(F)=C1 IYHOZKFNCBUEEM-UHFFFAOYSA-N 0.000 description 4
- BGLMJIVDFVKYIU-UHFFFAOYSA-N 2-amino-2-[2-[4-[5-(3-methylphenyl)sulfanylnaphthalen-1-yl]phenyl]ethyl]propane-1,3-diol Chemical compound CC1=CC=CC(SC=2C3=CC=CC(=C3C=CC=2)C=2C=CC(CCC(N)(CO)CO)=CC=2)=C1 BGLMJIVDFVKYIU-UHFFFAOYSA-N 0.000 description 4
- DJBXQJLGOGLGOO-UHFFFAOYSA-N 2-amino-2-[2-[4-[5-(4-methylphenyl)sulfanylnaphthalen-1-yl]phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1SC1=CC=CC2=C(C=3C=CC(CCC(N)(CO)CO)=CC=3)C=CC=C12 DJBXQJLGOGLGOO-UHFFFAOYSA-N 0.000 description 4
- WRXOZRLZDJAYDR-UHFFFAOYSA-N 3-methylbenzenethiol Chemical compound CC1=CC=CC(S)=C1 WRXOZRLZDJAYDR-UHFFFAOYSA-N 0.000 description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 description 4
- 101710155454 Sphingosine 1-phosphate receptor 1 Proteins 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 4
- LTYMSROWYAPPGB-UHFFFAOYSA-N diphenyl sulfide Chemical compound C=1C=CC=CC=1SC1=CC=CC=C1 LTYMSROWYAPPGB-UHFFFAOYSA-N 0.000 description 4
- PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 4
- 229960000556 fingolimod Drugs 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 238000007327 hydrogenolysis reaction Methods 0.000 description 4
- 230000001506 immunosuppresive effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 4
- 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 4
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 4
- 150000002941 palladium compounds Chemical class 0.000 description 4
- MUJIDPITZJWBSW-UHFFFAOYSA-N palladium(2+) Chemical compound [Pd+2] MUJIDPITZJWBSW-UHFFFAOYSA-N 0.000 description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical group COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 125000005556 thienylene group Chemical group 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 4
- 235000019798 tripotassium phosphate Nutrition 0.000 description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 3
- ZCWUQSVZPLUCOZ-UHFFFAOYSA-N 2-(4-bromo-2-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Br)C=C1Cl ZCWUQSVZPLUCOZ-UHFFFAOYSA-N 0.000 description 3
- JGKIPGSYCSLYAH-UHFFFAOYSA-N 2-amino-2-[2-[4-(2-fluoro-4-phenylsulfanylphenyl)phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=CC(CCC(CO)(CO)N)=CC=C1C(C(=C1)F)=CC=C1SC1=CC=CC=C1 JGKIPGSYCSLYAH-UHFFFAOYSA-N 0.000 description 3
- KNBYLHVGHHTTJU-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-(3-methoxyphenyl)sulfanylphenyl]phenyl]ethyl]propane-1,3-diol Chemical compound COC1=CC=CC(SC=2C=C(F)C(=CC=2)C=2C=CC(CCC(N)(CO)CO)=CC=2)=C1 KNBYLHVGHHTTJU-UHFFFAOYSA-N 0.000 description 3
- NMRRSFCJLNEAKO-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-(3-methylphenyl)sulfanylphenyl]phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.CC1=CC=CC(SC=2C=C(F)C(=CC=2)C=2C=CC(CCC(N)(CO)CO)=CC=2)=C1 NMRRSFCJLNEAKO-UHFFFAOYSA-N 0.000 description 3
- RLPOJQNAXALYDR-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-(4-methoxyphenyl)sulfanylphenyl]phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=CC(OC)=CC=C1SC1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)C(F)=C1 RLPOJQNAXALYDR-UHFFFAOYSA-N 0.000 description 3
- SKGUAUYGZVCFKD-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-(4-propan-2-ylphenyl)sulfanylphenyl]phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=CC(C(C)C)=CC=C1SC1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)C(F)=C1 SKGUAUYGZVCFKD-UHFFFAOYSA-N 0.000 description 3
- OWBOEKOQUOOSGJ-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(2,4-dimethylphenyl)sulfanyl-2-fluorophenyl]phenyl]ethyl]propane-1,3-diol Chemical compound CC1=CC(C)=CC=C1SC1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)C(F)=C1 OWBOEKOQUOOSGJ-UHFFFAOYSA-N 0.000 description 3
- FVLMXZNRSHEHLG-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(3,4-dimethylphenyl)sulfanyl-2-fluorophenyl]phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=C(C)C(C)=CC=C1SC1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)C(F)=C1 FVLMXZNRSHEHLG-UHFFFAOYSA-N 0.000 description 3
- ZUAQJCFFHOVOMS-UHFFFAOYSA-N 2-amino-2-ethyl-4-[4-[2-fluoro-4-(4-methylphenyl)sulfanylphenyl]phenyl]butan-1-ol Chemical compound C1=CC(CCC(N)(CO)CC)=CC=C1C(C(=C1)F)=CC=C1SC1=CC=C(C)C=C1 ZUAQJCFFHOVOMS-UHFFFAOYSA-N 0.000 description 3
- WPAXJRBYHHTTKZ-UHFFFAOYSA-N 2-amino-4-[4-[2-fluoro-4-(4-methylphenyl)sulfanylphenyl]phenyl]-2-methylbutan-1-ol;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1SC1=CC=C(C=2C=CC(CCC(C)(N)CO)=CC=2)C(F)=C1 WPAXJRBYHHTTKZ-UHFFFAOYSA-N 0.000 description 3
- XRMZKCQCINEBEI-UHFFFAOYSA-N 4-bromo-2-fluoro-1-iodobenzene Chemical compound FC1=CC(Br)=CC=C1I XRMZKCQCINEBEI-UHFFFAOYSA-N 0.000 description 3
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 description 3
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 description 3
- LRFKWQGGENFBFO-IBGZPJMESA-N [(2s)-2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl] dihydrogen phosphate Chemical compound CCCCCCCCC1=CC=C(CC[C@](N)(CO)COP(O)(O)=O)C=C1 LRFKWQGGENFBFO-IBGZPJMESA-N 0.000 description 3
- SKBVOWAKKLLDIM-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-(4-bromophenyl)butyl] acetate Chemical compound CC(=O)OCC(COC(C)=O)(NC(=O)C)CCC1=CC=C(Br)C=C1 SKBVOWAKKLLDIM-UHFFFAOYSA-N 0.000 description 3
- RNZWWYXAWMECRQ-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-[4-(4-bromo-2-fluorophenyl)-2-chlorophenyl]butyl] acetate Chemical compound C1=C(Cl)C(CCC(NC(=O)C)(COC(C)=O)COC(C)=O)=CC=C1C1=CC=C(Br)C=C1F RNZWWYXAWMECRQ-UHFFFAOYSA-N 0.000 description 3
- MNWXXIAUEAXEOR-UHFFFAOYSA-N [5-[4-[3-amino-4-hydroxy-3-(hydroxymethyl)butyl]phenyl]thiophen-2-yl]-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)S1 MNWXXIAUEAXEOR-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 239000007810 chemical reaction solvent Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- ZOCHARZZJNPSEU-UHFFFAOYSA-N diboron Chemical class B#B ZOCHARZZJNPSEU-UHFFFAOYSA-N 0.000 description 3
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 210000003563 lymphoid tissue Anatomy 0.000 description 3
- JSNXIWYWUKTWAX-UHFFFAOYSA-N methyl 4-bromo-2-chlorobenzoate Chemical compound COC(=O)C1=CC=C(Br)C=C1Cl JSNXIWYWUKTWAX-UHFFFAOYSA-N 0.000 description 3
- OBQMWEGANFPLMO-UHFFFAOYSA-N n-[4-(4-bromophenyl)-1-hydroxy-2-(hydroxymethyl)butan-2-yl]acetamide Chemical compound CC(=O)NC(CO)(CO)CCC1=CC=C(Br)C=C1 OBQMWEGANFPLMO-UHFFFAOYSA-N 0.000 description 3
- VOFJPJNMDXZLIM-UHFFFAOYSA-N n-[5-[2-(4-bromophenyl)ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C=1C=C(Br)C=CC=1CCC1(NC(=O)C)COC(C)(C)OC1 VOFJPJNMDXZLIM-UHFFFAOYSA-N 0.000 description 3
- 125000004957 naphthylene group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- 125000003944 tolyl group Chemical group 0.000 description 3
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 3
- PAQVZCDJJABVMB-UHFFFAOYSA-N (4-bromo-2-chlorophenyl)methanol Chemical compound OCC1=CC=C(Br)C=C1Cl PAQVZCDJJABVMB-UHFFFAOYSA-N 0.000 description 2
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- KGNQDBQYEBMPFZ-UHFFFAOYSA-N 1-fluoro-4-iodobenzene Chemical compound FC1=CC=C(I)C=C1 KGNQDBQYEBMPFZ-UHFFFAOYSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 2
- 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 2
- XXKHDSGLCLCFSC-UHFFFAOYSA-N 2,3-diphenylphenol Chemical compound C=1C=CC=CC=1C=1C(O)=CC=CC=1C1=CC=CC=C1 XXKHDSGLCLCFSC-UHFFFAOYSA-N 0.000 description 2
- MXZBZBHXAMJWMY-UHFFFAOYSA-N 2-(4-bromo-2-chlorophenyl)acetonitrile Chemical compound ClC1=CC(Br)=CC=C1CC#N MXZBZBHXAMJWMY-UHFFFAOYSA-N 0.000 description 2
- WAUUNSIHRYKSEY-UHFFFAOYSA-N 2-(4-bromo-2-chlorophenyl)ethanol Chemical compound OCCC1=CC=C(Br)C=C1Cl WAUUNSIHRYKSEY-UHFFFAOYSA-N 0.000 description 2
- SDTLNWHFSZTLOS-UHFFFAOYSA-N 2-amino-2-[2-[4-(4-bromo-2-fluorophenyl)phenyl]ethyl]propane-1,3-diol Chemical compound C1=CC(CCC(CO)(CO)N)=CC=C1C1=CC=C(Br)C=C1F SDTLNWHFSZTLOS-UHFFFAOYSA-N 0.000 description 2
- JFPBGTNQGCFOGQ-UHFFFAOYSA-N 2-amino-2-[2-[4-(5-phenylsulfanylnaphthalen-1-yl)phenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=CC(CCC(CO)(CO)N)=CC=C1C(C1=CC=C2)=CC=CC1=C2SC1=CC=CC=C1 JFPBGTNQGCFOGQ-UHFFFAOYSA-N 0.000 description 2
- USUMGUJZRMBTAB-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-(2-fluoro-4-methylphenyl)sulfanylphenyl]phenyl]ethyl]propane-1,3-diol Chemical compound FC1=CC(C)=CC=C1SC1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)C(F)=C1 USUMGUJZRMBTAB-UHFFFAOYSA-N 0.000 description 2
- JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical group CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 2
- JQTBWKNYWACCRU-UHFFFAOYSA-N 2-phenylsulfanylthiophene Chemical compound C=1C=CC=CC=1SC1=CC=CS1 JQTBWKNYWACCRU-UHFFFAOYSA-N 0.000 description 2
- IDKCKPBAFOIONK-UHFFFAOYSA-N 3,4-dimethylbenzenethiol Chemical compound CC1=CC=C(S)C=C1C IDKCKPBAFOIONK-UHFFFAOYSA-N 0.000 description 2
- VLRGXXKFHVJQOL-UHFFFAOYSA-N 3-chloropentane-2,4-dione Chemical compound CC(=O)C(Cl)C(C)=O VLRGXXKFHVJQOL-UHFFFAOYSA-N 0.000 description 2
- RDHPMPCJWBIULW-UHFFFAOYSA-N 4-(4-bromophenyl)-2-ethoxycarbonyl-2-ethylbutanoic acid Chemical compound CCOC(=O)C(CC)(C(O)=O)CCC1=CC=C(Br)C=C1 RDHPMPCJWBIULW-UHFFFAOYSA-N 0.000 description 2
- ZVBBQGJZAAGIRI-UHFFFAOYSA-N 4-(4-bromophenyl)-2-ethoxycarbonyl-2-methylbutanoic acid Chemical compound CCOC(=O)C(C)(C(O)=O)CCC1=CC=C(Br)C=C1 ZVBBQGJZAAGIRI-UHFFFAOYSA-N 0.000 description 2
- REBPXLNKELQFSY-UHFFFAOYSA-N 4-(ditert-butylphosphoryloxymethyl)-4-[2-[4-(2-fluoro-4-phenylsulfanylphenyl)phenyl]ethyl]-2-methyl-5h-1,3-oxazole Chemical compound C1OC(C)=NC1(COP(=O)(C(C)(C)C)C(C)(C)C)CCC1=CC=C(C=2C(=CC(SC=3C=CC=CC=3)=CC=2)F)C=C1 REBPXLNKELQFSY-UHFFFAOYSA-N 0.000 description 2
- SRTAWXUXLAGJEA-UHFFFAOYSA-N 4-(ditert-butylphosphoryloxymethyl)-4-[2-[4-[2-fluoro-4-(3-methylphenyl)sulfanylphenyl]phenyl]ethyl]-2-methyl-5h-1,3-oxazole Chemical compound C1OC(C)=NC1(COP(=O)(C(C)(C)C)C(C)(C)C)CCC1=CC=C(C=2C(=CC(SC=3C=C(C)C=CC=3)=CC=2)F)C=C1 SRTAWXUXLAGJEA-UHFFFAOYSA-N 0.000 description 2
- NJCPAYMXVMTIKZ-UHFFFAOYSA-N 4-(ditert-butylphosphoryloxymethyl)-4-[2-[4-[2-fluoro-4-(4-methylphenyl)sulfanylphenyl]phenyl]ethyl]-2-methyl-5h-1,3-oxazole Chemical compound C1OC(C)=NC1(COP(=O)(C(C)(C)C)C(C)(C)C)CCC1=CC=C(C=2C(=CC(SC=3C=CC(C)=CC=3)=CC=2)F)C=C1 NJCPAYMXVMTIKZ-UHFFFAOYSA-N 0.000 description 2
- ALOYBSVPNZSHEF-UHFFFAOYSA-N 4-[2-[4-(4-bromo-2-fluorophenyl)phenyl]ethyl]-4-(ditert-butylphosphoryloxymethyl)-2-methyl-5h-1,3-oxazole Chemical compound C1OC(C)=NC1(COP(=O)(C(C)(C)C)C(C)(C)C)CCC1=CC=C(C=2C(=CC(Br)=CC=2)F)C=C1 ALOYBSVPNZSHEF-UHFFFAOYSA-N 0.000 description 2
- DYPSDTOQOSPYOT-UHFFFAOYSA-N 4-bromo-1-(bromomethyl)-2-chlorobenzene Chemical compound ClC1=CC(Br)=CC=C1CBr DYPSDTOQOSPYOT-UHFFFAOYSA-N 0.000 description 2
- FYOIKHJHYDLNJY-UHFFFAOYSA-N 4-bromo-2-chloro-1-(2-iodoethyl)benzene Chemical compound ClC1=CC(Br)=CC=C1CCI FYOIKHJHYDLNJY-UHFFFAOYSA-N 0.000 description 2
- NIFAOMSJMGEFTQ-UHFFFAOYSA-N 4-methoxybenzenethiol Chemical compound COC1=CC=C(S)C=C1 NIFAOMSJMGEFTQ-UHFFFAOYSA-N 0.000 description 2
- APDUDRFJNCIWAG-UHFFFAOYSA-N 4-propan-2-ylbenzenethiol Chemical compound CC(C)C1=CC=C(S)C=C1 APDUDRFJNCIWAG-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- XGNWJEOUJHGKSM-UHFFFAOYSA-N CC1(COB(OC1)C1=CC=C(C=C1)CCC1COC(OC1)(C)C)C Chemical compound CC1(COB(OC1)C1=CC=C(C=C1)CCC1COC(OC1)(C)C)C XGNWJEOUJHGKSM-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- 239000005749 Copper compound Substances 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 239000012448 Lithium borohydride Substances 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- RYXZOQOZERSHHQ-UHFFFAOYSA-N [2-(2-diphenylphosphanylphenoxy)phenyl]-diphenylphosphane Chemical compound C=1C=CC=C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)C=1OC1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RYXZOQOZERSHHQ-UHFFFAOYSA-N 0.000 description 2
- QQLOJBSRJXZSJQ-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-(4-bromo-2-chlorophenyl)butyl] acetate Chemical compound CC(=O)OCC(COC(C)=O)(NC(=O)C)CCC1=CC=C(Br)C=C1Cl QQLOJBSRJXZSJQ-UHFFFAOYSA-N 0.000 description 2
- VLXDFOIBDQAFJR-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-[2-chloro-4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl]butyl] acetate Chemical compound C1=C(Cl)C(CCC(NC(=O)C)(COC(C)=O)COC(C)=O)=CC=C1B1OCC(C)(C)CO1 VLXDFOIBDQAFJR-UHFFFAOYSA-N 0.000 description 2
- IBHAAFJGRURWMR-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-[4-(2-fluoro-4-hydroxyphenyl)phenyl]butyl] acetate Chemical compound C1=CC(CCC(NC(=O)C)(COC(C)=O)COC(C)=O)=CC=C1C1=CC=C(O)C=C1F IBHAAFJGRURWMR-UHFFFAOYSA-N 0.000 description 2
- YAMPCUHZKKJWFT-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-[4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl]butyl] acetate Chemical compound C1=CC(CCC(NC(=O)C)(COC(C)=O)COC(C)=O)=CC=C1B1OCC(C)(C)CO1 YAMPCUHZKKJWFT-UHFFFAOYSA-N 0.000 description 2
- UAYBYWWJHGPMDT-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-[4-[2-fluoro-4-(4-methylphenoxy)phenyl]phenyl]butyl] acetate Chemical compound C1=CC(CCC(NC(=O)C)(COC(C)=O)COC(C)=O)=CC=C1C(C(=C1)F)=CC=C1OC1=CC=C(C)C=C1 UAYBYWWJHGPMDT-UHFFFAOYSA-N 0.000 description 2
- JEPAOSPQEPXJFY-UHFFFAOYSA-N [2-acetamido-4-[4-(4-bromo-2-fluorophenyl)phenyl]-2-ethylbutyl] acetate Chemical compound C1=CC(CCC(CC)(COC(C)=O)NC(C)=O)=CC=C1C1=CC=C(Br)C=C1F JEPAOSPQEPXJFY-UHFFFAOYSA-N 0.000 description 2
- OTNUTJHQLDKAOL-UHFFFAOYSA-N [2-acetamido-4-[4-(4-bromo-2-fluorophenyl)phenyl]-2-methylbutyl] acetate Chemical compound C1=CC(CCC(C)(NC(=O)C)COC(C)=O)=CC=C1C1=CC=C(Br)C=C1F OTNUTJHQLDKAOL-UHFFFAOYSA-N 0.000 description 2
- GIHUMPDEBHDMNL-UHFFFAOYSA-N [4-[4-[3-amino-4-hydroxy-3-(hydroxymethyl)butyl]phenyl]-3-fluorophenyl]-(4-methylphenyl)methanone;hydrochloride Chemical compound Cl.C1=CC(C)=CC=C1C(=O)C1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)C(F)=C1 GIHUMPDEBHDMNL-UHFFFAOYSA-N 0.000 description 2
- 150000001241 acetals Chemical class 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 150000005347 biaryls Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229940046731 calcineurin inhibitors Drugs 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 150000001880 copper compounds Chemical class 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 150000001923 cyclic compounds Chemical class 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- GTGNULBCYAMVIX-UHFFFAOYSA-N ethyl 4-(4-bromophenyl)-2-(methoxycarbonylamino)-2-methylbutanoate Chemical compound CCOC(=O)C(C)(NC(=O)OC)CCC1=CC=C(Br)C=C1 GTGNULBCYAMVIX-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 150000002690 malonic acid derivatives Chemical class 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- GYQSFCYMWAJKMD-UHFFFAOYSA-N methyl 2-(4-bromo-2-chlorophenyl)acetate Chemical compound COC(=O)CC1=CC=C(Br)C=C1Cl GYQSFCYMWAJKMD-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- JLIGUEAXMCSLAY-UHFFFAOYSA-N n-[2,2-dimethyl-5-[2-[4-[5-(4-methylbenzoyl)thiophen-2-yl]phenyl]ethyl]-1,3-dioxan-5-yl]acetamide Chemical compound C=1C=C(C=2SC(=CC=2)C(=O)C=2C=CC(C)=CC=2)C=CC=1CCC1(NC(=O)C)COC(C)(C)OC1 JLIGUEAXMCSLAY-UHFFFAOYSA-N 0.000 description 2
- XRMIZQZBENPNAI-UHFFFAOYSA-N n-[5-[2-[4-(5-formylthiophen-2-yl)phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C=1C=C(C=2SC(C=O)=CC=2)C=CC=1CCC1(NC(=O)C)COC(C)(C)OC1 XRMIZQZBENPNAI-UHFFFAOYSA-N 0.000 description 2
- FVWPJNGQUJHROJ-UHFFFAOYSA-N n-[5-[2-[4-[2-fluoro-4-(3-methoxyphenyl)sulfanylphenyl]phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound COC1=CC=CC(SC=2C=C(F)C(=CC=2)C=2C=CC(CCC3(COC(C)(C)OC3)NC(C)=O)=CC=2)=C1 FVWPJNGQUJHROJ-UHFFFAOYSA-N 0.000 description 2
- KSFKECMOXDXKIY-UHFFFAOYSA-N n-[5-[2-[4-[4-(2,4-dimethylphenyl)sulfanyl-2-fluorophenyl]phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C=1C=C(C=2C(=CC(SC=3C(=CC(C)=CC=3)C)=CC=2)F)C=CC=1CCC1(NC(=O)C)COC(C)(C)OC1 KSFKECMOXDXKIY-UHFFFAOYSA-N 0.000 description 2
- 229940105631 nembutal Drugs 0.000 description 2
- 150000001451 organic peroxides Chemical class 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000003003 phosphines Chemical class 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 229910001923 silver oxide Inorganic materials 0.000 description 2
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- XHFLOLLMZOTPSM-UHFFFAOYSA-M sodium;hydrogen carbonate;hydrate Chemical compound [OH-].[Na+].OC(O)=O XHFLOLLMZOTPSM-UHFFFAOYSA-M 0.000 description 2
- DUYSYHSSBDVJSM-KRWOKUGFSA-N sphingosine 1-phosphate Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)COP(O)(O)=O DUYSYHSSBDVJSM-KRWOKUGFSA-N 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- WWNKPFQHILWXEY-UHFFFAOYSA-N tert-butyl n-[4-(4-bromo-2-chlorophenyl)-1-hydroxy-2-(hydroxymethyl)butan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(CO)(CO)CCC1=CC=C(Br)C=C1Cl WWNKPFQHILWXEY-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 2
- MCVCQOAOORMKDL-UHFFFAOYSA-N (4-bromo-3-fluorophenyl)-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(Br)C(F)=C1 MCVCQOAOORMKDL-UHFFFAOYSA-N 0.000 description 1
- BIWQNIMLAISTBV-UHFFFAOYSA-N (4-methylphenyl)boronic acid Chemical compound CC1=CC=C(B(O)O)C=C1 BIWQNIMLAISTBV-UHFFFAOYSA-N 0.000 description 1
- VUAZMWGPDSBAHE-UHFFFAOYSA-N (5-phenylmethoxynaphthalen-1-yl) trifluoromethanesulfonate Chemical compound C1=CC=C2C(OS(=O)(=O)C(F)(F)F)=CC=CC2=C1OCC1=CC=CC=C1 VUAZMWGPDSBAHE-UHFFFAOYSA-N 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- 0 *c1cccc2c1cccc2OCc1ccccc1 Chemical compound *c1cccc2c1cccc2OCc1ccccc1 0.000 description 1
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 description 1
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 1
- PQPVYEDTTQIKIA-UHFFFAOYSA-N 1,2-dimethyl-9h-xanthene Chemical compound C1=CC=C2CC3=C(C)C(C)=CC=C3OC2=C1 PQPVYEDTTQIKIA-UHFFFAOYSA-N 0.000 description 1
- UJPKMTDFFUTLGM-UHFFFAOYSA-N 1-aminoethanol Chemical group CC(N)O UJPKMTDFFUTLGM-UHFFFAOYSA-N 0.000 description 1
- BYTJTXKQBSNGCL-UHFFFAOYSA-N 1-bromo-2-fluoro-4-phenylmethoxybenzene Chemical compound C1=C(Br)C(F)=CC(OCC=2C=CC=CC=2)=C1 BYTJTXKQBSNGCL-UHFFFAOYSA-N 0.000 description 1
- HNEGJTWNOOWEMH-UHFFFAOYSA-N 1-fluoropropane Chemical group [CH2]CCF HNEGJTWNOOWEMH-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- OHZAHWOAMVVGEL-UHFFFAOYSA-N 2,2'-bithiophene Chemical group C1=CSC(C=2SC=CC=2)=C1 OHZAHWOAMVVGEL-UHFFFAOYSA-N 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- AMNLXDDJGGTIPL-UHFFFAOYSA-N 2,4-dimethylbenzenethiol Chemical compound CC1=CC=C(S)C(C)=C1 AMNLXDDJGGTIPL-UHFFFAOYSA-N 0.000 description 1
- PMOSJSPFNDUAFY-UHFFFAOYSA-N 2-(4-bromophenyl)ethanol Chemical compound OCCC1=CC=C(Br)C=C1 PMOSJSPFNDUAFY-UHFFFAOYSA-N 0.000 description 1
- GXLDLBAEKWWRMB-UHFFFAOYSA-N 2-amino-2-[2-[4-(4-bromo-2-fluorophenyl)-2-chlorophenyl]ethyl]propane-1,3-diol;hydrochloride Chemical compound Cl.C1=C(Cl)C(CCC(CO)(CO)N)=CC=C1C1=CC=C(Br)C=C1F GXLDLBAEKWWRMB-UHFFFAOYSA-N 0.000 description 1
- WVXAIIPSUJHFPG-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-(3-fluorophenyl)sulfanylphenyl]phenyl]ethyl]propane-1,3-diol Chemical compound C1=CC(CCC(CO)(CO)N)=CC=C1C(C(=C1)F)=CC=C1SC1=CC=CC(F)=C1 WVXAIIPSUJHFPG-UHFFFAOYSA-N 0.000 description 1
- GEQHJYMHZMQQPN-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-(4-fluorophenyl)sulfanylphenyl]phenyl]ethyl]propane-1,3-diol Chemical compound C1=CC(CCC(CO)(CO)N)=CC=C1C(C(=C1)F)=CC=C1SC1=CC=C(F)C=C1 GEQHJYMHZMQQPN-UHFFFAOYSA-N 0.000 description 1
- NQZPZUAIEMKOHT-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-(5-methylthiophen-2-yl)sulfanylphenyl]phenyl]ethyl]propane-1,3-diol Chemical compound S1C(C)=CC=C1SC1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)C(F)=C1 NQZPZUAIEMKOHT-UHFFFAOYSA-N 0.000 description 1
- KCNVWEJOMWMFMO-UHFFFAOYSA-N 2-amino-2-[2-[4-[2-fluoro-4-[4-(trifluoromethyl)phenyl]sulfanylphenyl]phenyl]ethyl]propane-1,3-diol Chemical compound C1=CC(CCC(CO)(CO)N)=CC=C1C(C(=C1)F)=CC=C1SC1=CC=C(C(F)(F)F)C=C1 KCNVWEJOMWMFMO-UHFFFAOYSA-N 0.000 description 1
- ROTMQVKHHRIZRI-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(4-chlorophenyl)sulfanyl-2-fluorophenyl]phenyl]ethyl]propane-1,3-diol Chemical compound C1=CC(CCC(CO)(CO)N)=CC=C1C(C(=C1)F)=CC=C1SC1=CC=C(Cl)C=C1 ROTMQVKHHRIZRI-UHFFFAOYSA-N 0.000 description 1
- MPRXPTXKECNTDD-UHFFFAOYSA-N 2-amino-2-[2-[4-[4-(4-ethylphenyl)sulfanyl-2-fluorophenyl]phenyl]ethyl]propane-1,3-diol Chemical compound C1=CC(CC)=CC=C1SC1=CC=C(C=2C=CC(CCC(N)(CO)CO)=CC=2)C(F)=C1 MPRXPTXKECNTDD-UHFFFAOYSA-N 0.000 description 1
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 1
- VLXWEUASWRQBAY-UHFFFAOYSA-N 2-fluoro-4-methylbenzenethiol Chemical compound CC1=CC=C(S)C(F)=C1 VLXWEUASWRQBAY-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- GUXJXWKCUUWCLX-UHFFFAOYSA-N 2-methyl-2-oxazoline Chemical compound CC1=NCCO1 GUXJXWKCUUWCLX-UHFFFAOYSA-N 0.000 description 1
- ZDEUGINAVLMAET-UHFFFAOYSA-N 3-fluorobenzenethiol Chemical compound FC1=CC=CC(S)=C1 ZDEUGINAVLMAET-UHFFFAOYSA-N 0.000 description 1
- QMVAZEHZOPDGHA-UHFFFAOYSA-N 3-methoxybenzenethiol Chemical compound COC1=CC=CC(S)=C1 QMVAZEHZOPDGHA-UHFFFAOYSA-N 0.000 description 1
- DOFIAZGYBIBEGI-UHFFFAOYSA-N 3-sulfanylphenol Chemical compound OC1=CC=CC(S)=C1 DOFIAZGYBIBEGI-UHFFFAOYSA-N 0.000 description 1
- WCMLRSZJUIKVCW-UHFFFAOYSA-N 4-(trifluoromethyl)benzenethiol Chemical compound FC(F)(F)C1=CC=C(S)C=C1 WCMLRSZJUIKVCW-UHFFFAOYSA-N 0.000 description 1
- OKIHXNKYYGUVTE-UHFFFAOYSA-N 4-Fluorothiophenol Chemical compound FC1=CC=C(S)C=C1 OKIHXNKYYGUVTE-UHFFFAOYSA-N 0.000 description 1
- MURRROPNZSNCEL-UHFFFAOYSA-N 4-[2-[2-chloro-4-[2-fluoro-4-(4-methylphenyl)sulfanylphenyl]phenyl]ethyl]-4-(ditert-butylphosphoryloxymethyl)-2-methyl-5h-1,3-oxazole Chemical compound C1OC(C)=NC1(COP(=O)(C(C)(C)C)C(C)(C)C)CCC1=CC=C(C=2C(=CC(SC=3C=CC(C)=CC=3)=CC=2)F)C=C1Cl MURRROPNZSNCEL-UHFFFAOYSA-N 0.000 description 1
- XVKIZRCGIJIFTC-UHFFFAOYSA-N 4-[2-[4-(4-bromo-2-fluorophenyl)-2-chlorophenyl]ethyl]-4-(ditert-butylphosphoryloxymethyl)-2-methyl-5h-1,3-oxazole Chemical compound C1OC(C)=NC1(COP(=O)(C(C)(C)C)C(C)(C)C)CCC1=CC=C(C=2C(=CC(Br)=CC=2)F)C=C1Cl XVKIZRCGIJIFTC-UHFFFAOYSA-N 0.000 description 1
- ZDRVLAOYDGQLFI-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-1,3-thiazol-2-yl]amino]phenol;hydrochloride Chemical compound Cl.C1=CC(O)=CC=C1NC1=NC(C=2C=CC(Cl)=CC=2)=CS1 ZDRVLAOYDGQLFI-UHFFFAOYSA-N 0.000 description 1
- JAVZWSOFJKYSDY-UHFFFAOYSA-N 4-bromo-2-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C=C1Cl JAVZWSOFJKYSDY-UHFFFAOYSA-N 0.000 description 1
- SLYYEMJPXWFKDE-UHFFFAOYSA-N 4-bromo-3-fluoro-n-methoxy-n-methylbenzamide Chemical compound CON(C)C(=O)C1=CC=C(Br)C(F)=C1 SLYYEMJPXWFKDE-UHFFFAOYSA-N 0.000 description 1
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 1
- WWQQPHUHTAZWDH-UHFFFAOYSA-N 4-ethylbenzenethiol Chemical compound CCC1=CC=C(S)C=C1 WWQQPHUHTAZWDH-UHFFFAOYSA-N 0.000 description 1
- IHTLZNZYAZTKSG-UHFFFAOYSA-N 5-methylthiophene-2-thiol Chemical compound CC1=CC=C(S)S1 IHTLZNZYAZTKSG-UHFFFAOYSA-N 0.000 description 1
- CQLOZFAXMGWIAT-UHFFFAOYSA-N 5-phenylmethoxynaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=CC2=C1OCC1=CC=CC=C1 CQLOZFAXMGWIAT-UHFFFAOYSA-N 0.000 description 1
- MTVNAPYHLASOSX-UHFFFAOYSA-N 9,9-dimethylxanthene Chemical compound C1=CC=C2C(C)(C)C3=CC=CC=C3OC2=C1 MTVNAPYHLASOSX-UHFFFAOYSA-N 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- RONTUNOEPKXNNX-UHFFFAOYSA-N CC(C)(C)OP(OCC1(CCc(cc2)ccc2-c(c(F)c2)ccc2Br)N=C(C)OC1)(OC(C)(C)C)=O Chemical compound CC(C)(C)OP(OCC1(CCc(cc2)ccc2-c(c(F)c2)ccc2Br)N=C(C)OC1)(OC(C)(C)C)=O RONTUNOEPKXNNX-UHFFFAOYSA-N 0.000 description 1
- PFFWJICEVCZJKP-UHFFFAOYSA-N CC(C)(C)OP(OCC1(CCc(cc2)ccc2-c(c(F)c2)ccc2Sc2cccc(C)c2)N=C(C)OC1)(OC(C)(C)C)=O Chemical compound CC(C)(C)OP(OCC1(CCc(cc2)ccc2-c(c(F)c2)ccc2Sc2cccc(C)c2)N=C(C)OC1)(OC(C)(C)C)=O PFFWJICEVCZJKP-UHFFFAOYSA-N 0.000 description 1
- VOOFLKWQVMOWKC-UHFFFAOYSA-N CC(C)(C)OP(OCC1(CCc(ccc(-c(c(F)c2)ccc2Sc2ccc(C)cc2)c2)c2Cl)N=C(C)OC1)(OC(C)(C)C)=O Chemical compound CC(C)(C)OP(OCC1(CCc(ccc(-c(c(F)c2)ccc2Sc2ccc(C)cc2)c2)c2Cl)N=C(C)OC1)(OC(C)(C)C)=O VOOFLKWQVMOWKC-UHFFFAOYSA-N 0.000 description 1
- USQFXMUZWZHSGZ-UIOVPNJHSA-N CC(C)[O](C)[C@@H](C)[C@H]([C@@H](C)[C@H](C)C/C=C(/[C@H](C[C@H](C)C1)C[C@H]1F)\C(C)=C)N Chemical compound CC(C)[O](C)[C@@H](C)[C@H]([C@@H](C)[C@H](C)C/C=C(/[C@H](C[C@H](C)C1)C[C@H]1F)\C(C)=C)N USQFXMUZWZHSGZ-UIOVPNJHSA-N 0.000 description 1
- DMBZPISJELHKCU-UHFFFAOYSA-N CC(NC(CCc(cc1)ccc1-c1c(cccc2OCc3ccccc3)c2ccc1)(COC(C)=O)COC(C)=O)=O Chemical compound CC(NC(CCc(cc1)ccc1-c1c(cccc2OCc3ccccc3)c2ccc1)(COC(C)=O)COC(C)=O)=O DMBZPISJELHKCU-UHFFFAOYSA-N 0.000 description 1
- PTZSDGSIPGJRLN-UHFFFAOYSA-N CCN(CC)C(C(=O)O)C(=O)OC(=O)OC(C)(C)C Chemical compound CCN(CC)C(C(=O)O)C(=O)OC(=O)OC(C)(C)C PTZSDGSIPGJRLN-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- KTGKLUROCSZBIV-UHFFFAOYSA-N Cc(cc1)ccc1C(c1ccc(-c2ccc(CCC(CO)(CO)N)cc2)c(F)c1)=O Chemical compound Cc(cc1)ccc1C(c1ccc(-c2ccc(CCC(CO)(CO)N)cc2)c(F)c1)=O KTGKLUROCSZBIV-UHFFFAOYSA-N 0.000 description 1
- IBRAQNMKKXRCPA-UHFFFAOYSA-N Cc1cc(Sc(cc2)cc(F)c2C2=CCC(CCC(CO)(COP(O)(O)=O)N)C=C2)ccc1 Chemical compound Cc1cc(Sc(cc2)cc(F)c2C2=CCC(CCC(CO)(COP(O)(O)=O)N)C=C2)ccc1 IBRAQNMKKXRCPA-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZKWAVXPQAYNCRM-UHFFFAOYSA-N Cl.BrC1=CC(=C(C=C1)C1=CC(=C(C=C1)CCC(CO)CO)Cl)F Chemical compound Cl.BrC1=CC(=C(C=C1)C1=CC(=C(C=C1)CCC(CO)CO)Cl)F ZKWAVXPQAYNCRM-UHFFFAOYSA-N 0.000 description 1
- WJTSRUUBCIBFMS-UHFFFAOYSA-N ClC(C(C)(C)P(O)(=O)C(C)(C)C)Cl Chemical compound ClC(C(C)(C)P(O)(=O)C(C)(C)C)Cl WJTSRUUBCIBFMS-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 102100025749 Sphingosine 1-phosphate receptor 2 Human genes 0.000 description 1
- 101710155462 Sphingosine 1-phosphate receptor 2 Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 238000006069 Suzuki reaction reaction Methods 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- JEDOWGMLRDSTLY-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-[2-chloro-4-[2-fluoro-4-(4-methylphenyl)sulfanylphenyl]phenyl]butyl] acetate Chemical compound C1=C(Cl)C(CCC(NC(=O)C)(COC(C)=O)COC(C)=O)=CC=C1C(C(=C1)F)=CC=C1SC1=CC=C(C)C=C1 JEDOWGMLRDSTLY-UHFFFAOYSA-N 0.000 description 1
- VZALCNLDUWUBGN-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]butyl] acetate Chemical compound C1=CC(CCC(NC(=O)C)(COC(C)=O)COC(C)=O)=CC=C1B1OC(C)(C)C(C)(C)O1 VZALCNLDUWUBGN-UHFFFAOYSA-N 0.000 description 1
- MEVYYUGEIWSKMM-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-[4-(5-hydroxynaphthalen-1-yl)phenyl]butyl] acetate Chemical compound C1=CC(CCC(NC(=O)C)(COC(C)=O)COC(C)=O)=CC=C1C1=CC=CC2=C(O)C=CC=C12 MEVYYUGEIWSKMM-UHFFFAOYSA-N 0.000 description 1
- SGUWLTGMLZEJLT-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-[4-(5-phenylsulfanylnaphthalen-1-yl)phenyl]butyl] acetate Chemical compound C1=CC(CCC(NC(=O)C)(COC(C)=O)COC(C)=O)=CC=C1C(C1=CC=C2)=CC=CC1=C2SC1=CC=CC=C1 SGUWLTGMLZEJLT-UHFFFAOYSA-N 0.000 description 1
- MMQDBHGZGAQODH-UHFFFAOYSA-N [2-acetamido-2-(acetyloxymethyl)-4-[4-[5-(trifluoromethylsulfonyloxy)naphthalen-1-yl]phenyl]butyl] acetate Chemical compound C1=CC(CCC(NC(=O)C)(COC(C)=O)COC(C)=O)=CC=C1C1=CC=CC2=C(OS(=O)(=O)C(F)(F)F)C=CC=C12 MMQDBHGZGAQODH-UHFFFAOYSA-N 0.000 description 1
- RJPUWMMGZSHRMN-UHFFFAOYSA-N [2-acetamido-4-[4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl]-2-ethylbutyl] acetate Chemical compound C1=CC(CCC(CC)(COC(C)=O)NC(C)=O)=CC=C1B1OCC(C)(C)CO1 RJPUWMMGZSHRMN-UHFFFAOYSA-N 0.000 description 1
- GELXHZNMLASFCL-UHFFFAOYSA-N [2-acetamido-4-[4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl]-2-methylbutyl] acetate Chemical compound C1=CC(CCC(C)(NC(=O)C)COC(C)=O)=CC=C1B1OCC(C)(C)CO1 GELXHZNMLASFCL-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- RFUHYBGHIJSEHB-VGOFMYFVSA-N chembl1241127 Chemical compound C1=C(O)C(/C=N/O)=CC=C1C1=CC(O)=CC(O)=C1 RFUHYBGHIJSEHB-VGOFMYFVSA-N 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- USVZFSNDGFNNJT-UHFFFAOYSA-N cyclopenta-1,4-dien-1-yl(diphenyl)phosphane (2,3-dichlorocyclopenta-1,4-dien-1-yl)-diphenylphosphane iron(2+) Chemical compound [Fe++].c1cc[c-](c1)P(c1ccccc1)c1ccccc1.Clc1c(cc[c-]1Cl)P(c1ccccc1)c1ccccc1 USVZFSNDGFNNJT-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 125000003963 dichloro group Chemical group Cl* 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- DQOTTXGAMXICQT-UHFFFAOYSA-N diethyl 2-[2-(4-bromo-2-chlorophenyl)ethyl]-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanedioate Chemical compound CC(C)(C)OC(=O)NC(C(=O)OCC)(C(=O)OCC)CCC1=CC=C(Br)C=C1Cl DQOTTXGAMXICQT-UHFFFAOYSA-N 0.000 description 1
- CYOXGWUPLSKLIC-UHFFFAOYSA-N diethyl 2-[2-(4-bromophenyl)ethyl]-2-methylpropanedioate Chemical compound CCOC(=O)C(C)(C(=O)OCC)CCC1=CC=C(Br)C=C1 CYOXGWUPLSKLIC-UHFFFAOYSA-N 0.000 description 1
- ISOLMABRZPQKOV-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate Chemical compound CCOC(=O)C(NC(C)=O)C(=O)OCC ISOLMABRZPQKOV-UHFFFAOYSA-N 0.000 description 1
- VQAZCUCWHIIFGE-UHFFFAOYSA-N diethyl 2-ethylpropanedioate Chemical compound CCOC(=O)C(CC)C(=O)OCC VQAZCUCWHIIFGE-UHFFFAOYSA-N 0.000 description 1
- UPQZOUHVTJNGFK-UHFFFAOYSA-N diethyl 2-methylpropanedioate Chemical compound CCOC(=O)C(C)C(=O)OCC UPQZOUHVTJNGFK-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- RKTKWZAIKQNOIU-UHFFFAOYSA-N ditert-butylphosphinous acid Chemical compound CC(C)(C)P(O)C(C)(C)C RKTKWZAIKQNOIU-UHFFFAOYSA-N 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 239000004210 ether based solvent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 1
- 125000001207 fluorophenyl group Chemical group 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- YAMQOOCGNXAQGW-UHFFFAOYSA-M magnesium;methylbenzene;bromide Chemical compound [Mg+2].[Br-].CC1=CC=CC=[C-]1 YAMQOOCGNXAQGW-UHFFFAOYSA-M 0.000 description 1
- BVUQKCCKUOSAEV-UHFFFAOYSA-M magnesium;methylbenzene;bromide Chemical compound [Mg+2].[Br-].CC1=CC=[C-]C=C1 BVUQKCCKUOSAEV-UHFFFAOYSA-M 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- KVKFRMCSXWQSNT-UHFFFAOYSA-N n,n'-dimethylethane-1,2-diamine Chemical compound CNCCNC KVKFRMCSXWQSNT-UHFFFAOYSA-N 0.000 description 1
- XZWGVQAOSLFADP-UHFFFAOYSA-N n-[5-[2-[4-(2-fluoro-4-phenylsulfanylphenyl)phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C=1C=C(C=2C(=CC(SC=3C=CC=CC=3)=CC=2)F)C=CC=1CCC1(NC(=O)C)COC(C)(C)OC1 XZWGVQAOSLFADP-UHFFFAOYSA-N 0.000 description 1
- VUYVPFGJJCPEKK-UHFFFAOYSA-N n-[5-[2-[4-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C=1C=C(B2OCC(C)(C)CO2)C=CC=1CCC1(NC(=O)C)COC(C)(C)OC1 VUYVPFGJJCPEKK-UHFFFAOYSA-N 0.000 description 1
- STKIGCFXXHWDOQ-UHFFFAOYSA-N n-[5-[2-[4-[2-fluoro-4-(3-methylphenyl)sulfanylphenyl]phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C=1C=C(C=2C(=CC(SC=3C=C(C)C=CC=3)=CC=2)F)C=CC=1CCC1(NC(=O)C)COC(C)(C)OC1 STKIGCFXXHWDOQ-UHFFFAOYSA-N 0.000 description 1
- XJISTACKHIRNGT-UHFFFAOYSA-N n-[5-[2-[4-[2-fluoro-4-(4-methoxyphenyl)sulfanylphenyl]phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C1=CC(OC)=CC=C1SC1=CC=C(C=2C=CC(CCC3(COC(C)(C)OC3)NC(C)=O)=CC=2)C(F)=C1 XJISTACKHIRNGT-UHFFFAOYSA-N 0.000 description 1
- BMYSRZDNTUINBD-UHFFFAOYSA-N n-[5-[2-[4-[2-fluoro-4-(4-methylphenyl)sulfanylphenyl]phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C=1C=C(C=2C(=CC(SC=3C=CC(C)=CC=3)=CC=2)F)C=CC=1CCC1(NC(=O)C)COC(C)(C)OC1 BMYSRZDNTUINBD-UHFFFAOYSA-N 0.000 description 1
- DWUNCUGALIHQCG-UHFFFAOYSA-N n-[5-[2-[4-[2-fluoro-4-(4-propan-2-ylphenyl)sulfanylphenyl]phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C1=CC(C(C)C)=CC=C1SC1=CC=C(C=2C=CC(CCC3(COC(C)(C)OC3)NC(C)=O)=CC=2)C(F)=C1 DWUNCUGALIHQCG-UHFFFAOYSA-N 0.000 description 1
- YWOGJMRCATWDBQ-UHFFFAOYSA-N n-[5-[2-[4-[4-(3,4-dimethylphenyl)sulfanyl-2-fluorophenyl]phenyl]ethyl]-2,2-dimethyl-1,3-dioxan-5-yl]acetamide Chemical compound C=1C=C(C=2C(=CC(SC=3C=C(C)C(C)=CC=3)=CC=2)F)C=CC=1CCC1(NC(=O)C)COC(C)(C)OC1 YWOGJMRCATWDBQ-UHFFFAOYSA-N 0.000 description 1
- KUKSUQKELVOKBH-UHFFFAOYSA-N n-[bis[(2-methylpropan-2-yl)oxy]phosphanyl]-n-ethylethanamine Chemical compound CCN(CC)P(OC(C)(C)C)OC(C)(C)C KUKSUQKELVOKBH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 150000002940 palladium Chemical class 0.000 description 1
- JGBZTJWQMWZVNX-UHFFFAOYSA-N palladium;tricyclohexylphosphane Chemical compound [Pd].C1CCCCC1P(C1CCCCC1)C1CCCCC1.C1CCCCC1P(C1CCCCC1)C1CCCCC1 JGBZTJWQMWZVNX-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000005004 perfluoroethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000005551 pyridylene group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002683 reaction inhibitor Substances 0.000 description 1
- 229940075993 receptor modulator Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 108010035597 sphingosine kinase Proteins 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229910021515 thallium hydroxide Inorganic materials 0.000 description 1
- QGYXCSSUHCHXHB-UHFFFAOYSA-M thallium(i) hydroxide Chemical compound [OH-].[Tl+] QGYXCSSUHCHXHB-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000005557 thiazolylene group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- ARYHTUPFQTUBBG-UHFFFAOYSA-N thiophen-2-ylboronic acid Chemical compound OB(O)C1=CC=CS1 ARYHTUPFQTUBBG-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
- C07C225/16—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/63—Esters of sulfonic acids
- C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
- C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/38—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with the sulfur atom of the thio group bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
- C07C323/40—Y being a hydrogen or a carbon atom
- C07C323/41—Y being a hydrogen or an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(1)下記一般式(I)
b.2−アミノ−4−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]−2−(ホスホリルオキシメチル)ブタノール
(8)2−アミノ−2−{2−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール、又はその塩酸塩。
(12)一般式(II−1)で表される脱離基Xcを有するベンゼン化合物と一般式(II−2)で表されるベンゼンチオールとを縮合させることを特徴とする、一般式(II−3)で表される化合物の製造方法。
(13)一般式(II−1’)で表されるチオール化合物と一般式(II−2’)で表される脱離基Xcを有するベンゼン化合物とを縮合させることを特徴とする、一般式(II−3)で表される化合物の製造方法。
(1)2−アミノ−2−{2−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール、
(2)2−アミノ−4−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]−2−(ホスホリルオキシメチル)ブタノール。
1)本発明化合物のうち、一般式(I)中のR1が水素原子で表されるもの(I−1)は以下のスキーム(III)により合成される。
式中のRaは水素原子又は水酸基を保護するものであれば特に限定されない。例えば、アシル(好ましくは炭素数2〜4程度のもの、具体的にはアセチルなど)、トリアルキルシリル(具体的にはトリメチルシリルなど)、ベンジル又はアセタールを形成する保護基(具体的にはメトキシメチル、テトラヒドロピラニルなど)が挙げられる。また、R8に保護された水酸基が含まれる場合、その保護基Rc(RcとしてはRaと同様のものが挙げられる)とRaが結合し、環状のアセタールを形成することもできる。式中のRbは水素原子又はアミノ基を保護するものであれば特に限定されない。例えば、アシル(好ましくは炭素数2〜4程度のもの、具体的にはアセチルなど)、カルバメート(具体的にはt−ブトキシカルボニルやベンジルオキシカルボニル)等が挙げられる。Xa、Xb、Xcで示される脱離基は、活性化基Yaの導入反応又は縮合反応時に脱離するものであれば特に限定されない。例えば、ハロゲン原子(好ましくはヨウ素原子、臭素原子など)、トリフルオロメタンスルホニルオキシ等が挙げられる。Yaで示される活性化基としてはリチウムやマグネシウム等の金属を含んだ置換基、又はケイ素やホウ素等の非金属元素を含む置換基があげられる。上記脱離基と活性化基は縮合反応の種類に応じて適切な組み合わせで用いられる。
式中のRdで示される保護基はアミノ基を保護するものであれば特に限定されない。例えば、アシル(好ましくは炭素数2〜4程度のもの、具体的にはアセチルなど)、カルバメート(具体的にはt−ブトキシカルボニルやベンジルオキシカルボニル)等が挙げられる。また化合物(I−1)のR2に水酸基が含まれる場合、その水酸基も保護基Rc(Rcは前述と同義)で保護できるが、R2がヒドロキシメチルやヒドロキシエチルの場合、以下のような環状化合物(IV−1a、IV−1b)
を形成することによって、アミノ基及びR2に含まれる水酸基を保護することもできる。式中のReで示される保護基としてはリン酸基を保護するものであれば特に限定されない。例えばアルキル(好ましくは炭素数1〜6程度のもの、具体的にはt−ブチルなど)、ベンジル、フェニル等が挙げられる。
式中のRa、Rb、Rd、Re及びXcで表される保護基及び脱離基は、スキーム(III)及びスキーム(IV)で述べたものと同じものが挙げられる。また化合物(V−1)のR2に水酸基が含まれる場合、その水酸基も保護基Rc(Rcは前述と同義)で保護できるが、R2がヒドロキシメチルやヒドロキシエチルの場合、下記のような環状化合物(V−2a、V−2b)
を形成することによって、アミノ基及びR2に含まれる水酸基を保護することもできる。
Ra、Rb、Xcの具体的な例としては、スキーム(III)で挙げたものと同様のものが挙げられる。R8の保護されていても良い水酸基の保護基Rcとしては、Raと同様のものが挙げられるが、RcとRaが結合し、環状のアセタールを形成することもできる。Aの置換されていても良いアリーレン及び置換されていても良いヘテロアリーレンの具体例としてはAr1と同様のものが挙げられる。Ar3の置換されていても良いアリール及び置換されていても良いヘテロアリールの具体例としてはAr2と同様のものが挙げられる。Ar3の「保護されていても良い水酸基で置換されたフェニル」における水酸基の保護基としては、反応中に脱離しないものであれば特に限定されないが、メトキシメチル、ベンジルオキシメチル、テトラヒドロピラニル等のアセタールを形成する保護基、トリメチルシリル等のシリルエーテル、メチル等のエーテル、アセチル、メトキシカルボニル等のアシル等が挙げられる。上記式(II−1)、(II−2)、(II−3)、(II−1’)及び(II−2’)において、R8の好ましい例としては水酸基が保護されていても良いヒドロキシメチル、より好ましい例としてはアセトキシメチル、R3の好ましい例としては水素原子、Ar3の好ましい例としては置換されていても良いアリール、より好ましい例としてはメチルフェニル、Aの好ましい例としては置換されていても良いアリーレン、より好ましい例としては
上記式(II−4)において、R2の好ましい例としてはヒドロキシメチル、R3の好ましい例としては水素原子、Ar4の好ましい例としては置換されていても良いアリール、より好ましい例としてはメチルフェニル、Aの好ましい例としては置換されていても良いアリーレン、より好ましい例としては
トリフルオロメタンスルホン酸 5−ベンジルオキシナフタレン−1−イルエステル
1H−NMR(DMSO−d6)δ(ppm):5.37(2H、s)、7.28−7.73(10H、m)、8.34(1H、d、J=8.2Hz)。
2−(4−ブロモフェニル)エチルヨージド
1H−NMR(CDCl3)δ(ppm):3.13(2H、t、J=7.7Hz)、3.32(2H、d、J=7.4Hz)、7.07(2H、d、J=8.4Hz)、7.44(2H、d、J=8.1Hz)。
2−アセタミド−2−[2−(4−ブロモフェニル)エチル]マロン酸ジエチル
1H−NMR(CDCl3)δ(ppm):1.25(6H、t、J=7.2Hz)、1.99(3H、s)、2.41−2.46(2H、m)、2.64−2.69(2H、m)、4.16−4.29(4H、m)、6.75(1H、s)、7.02(2H、d、J=8.4Hz)、7.38(2H、d、J=8.1Hz)。
N−[3−(4−ブロモフェニル)−1,1−ビス(ヒドロキシメチル)プロピル]アセタミド
1H−NMR(DMSO−d6)δ(ppm):1.81−1.87(5H、m)、2.45−2.51(2H、m)、3.46(2H、dd、J=6.9、11.1Hz)、3.56(2H、dd、J=5.7、10.8Hz)、4.81(2H、t、J=5.7Hz)、7.14(2H、d、J=8.1Hz)、7.44(2H、d、J=8.4Hz)。
N−{5−[2−(4−ブロモフェニル)エチル]−2,2−ジメチル−1,3−ジオキサン−5−イル}アセタミド
1H−NMR(CDCl3)δ(ppm):1.43(6H、s)、2.03(3H、s)、2.01−2.06(2H、m)、2.46−2.52(2H、m)、3.67(2H、d、J=11.7Hz)、3.95(2H、d、J=11.7Hz)、5.76(1H、s)、7.05(2H、d、J=8.4Hz)、7.38(2H、d、J=8.4Hz)。
N−(5−{2−[4−(5,5−ジメチル−1,3,2−ジオキサボリナン−2−イル)フェニル]エチル}−2,2−ジメチル−1,3−ジオキサン−5−イル)アセタミド
1H−NMR(CDCl3)δ(ppm):1.01(6H、s)、1.42(6H、s)、2.02(3H、s)、2.03−2.09(2H、m)、2.53−2.58(2H、m)、3.66(2H、d、J=11.7Hz)、3.76(4H、s)、3.97(2H、d、J=12.0Hz)、5.71(1H、s)、7.17(2H、d、J=8.1Hz)、7.70(2H、d、J=7.8Hz)。
N−[1,1−ビス(アセトキシメチル)−3−(4−ブロモフェニル)プロピル]アセタミド
1H−NMR(CDCl3)δ(ppm):1.99(3H、s)、2.10(6H、s)、2.16−2.22(2H、m)、2.53−2.59(2H、m)、4.33(4H、s)、5.73(1H、s)、7.06(2H、d、J=8.1Hz)、7.39(2H、d、J=8.7Hz)。
N−{1,1−ビス(アセトキシメチル)−3−[4−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)フェニル]プロピル}アセタミド
1H−NMR(DMSO−d6)δ(ppm):1.28(12H、s)、1.85(3H、s)、1.93−1.97(2H、m)、2.02(6H、s)、2.50−2.56(2H、m)、4.19(2H、d、J=11.0Hz)、4.28(2H、d、J=11.0Hz)、7.19(2H、d、J=7.8Hz)、7.59(2H、d、J=7.8Hz)、7.68(1H、s)。
N−{1,1−ビス(アセトキシメチル)−3−[4−(5,5−ジメチル−1,3,2−ジオキサボリナン−2−イル)フェニル]プロピル}アセタミド
1H−NMR(CDCl3)δ(ppm):1.02(6H、s)、1.95(3H、s)、2.09(6H、s)、2.17−2.23(2H、m)、2.59−2.65(2H、m)、3.76(4H、s)、4.35(4H、m)、5.65(1H、s)、7.18(2H、d、J=7.9Hz)、7.72(2H、d、J=7.8Hz)。
N−{5−[2−(4’−ブロモ−2’−フルオロビフェニル−4−イル)エチル]−2,2−ジメチル−1,3−ジオキサン−5−イル}アセタミド
1H−NMR(DMSO−d6)δ(ppm):1.35(6H、s)、1.87(3H、s)、1.98−2.04(2H、m)、2.47−2.53(2H、m)、3.71(2H、d、J=11.8Hz)、3.97(2H、d、J=11.6Hz)、7.27(2H、d、J=8.1Hz)、7.44−7.53(3H、m)、7.61−7.66(2H、m)。
4−ブロモ−2−クロロ安息香酸メチル
1H−NMR(CDCl3)δ(ppm):3.93(3H、s)、7.46(1H、dd、J=1.8、8.4Hz)、7.64(1H、d、J=1.8Hz)、7.72(1H、d、J=8.4Hz)。
4−ブロモ−2−クロロベンジルアルコール
1H−NMR(CDCl3)δ(ppm):1.87(1H、t、J=5.8Hz)、4.74(2H、d、J=5.8Hz)、7.38(1H、d、J=8.2Hz)、7.42(1H、dd、J=1.8、8.2Hz)、7.53(1H、d、J=1.8Hz)。
4−ブロモ−2−クロロベンジルブロミド
1H−NMR(CDCl3)δ(ppm):4.53(2H、s)、7.31(1H、d、J=8.2Hz)、7.39(1H、dd、J=1.8、8.2Hz)、7.56(1H、d、J=1.8Hz)。
4−ブロモ−2−クロロベンジルシアニド
1H−NMR(CDCl3)δ(ppm):3.79(2H、s)、7.40(1H、d、J=8.2Hz)、7.46(1H、dd、J=1.8、8.2Hz)、7.60(1H、d、J=1.8Hz)。
4−ブロモ−2−クロロフェニル酢酸
1H−NMR(CDCl3)δ(ppm):3.78(2H、s)、7.17(1H、d、J=8.2Hz)、7.38(1H、dd、J=1.8、8.2Hz)、7.57(1H、d、J=1.8Hz)。
4−ブロモ−2−クロロフェニル酢酸メチルエステル
1H−NMR(CDCl3)δ(ppm):3.71(3H、s)、3.73(2H、s)、7.16(1H、d、J=8.2Hz)、7.37(1H、dd、J=2.0、8.2Hz)、7.56(1H、d、J=2.0Hz)。
2−(4−ブロモ−2−クロロフェニル)エタノール
1H−NMR(CDCl3)δ(ppm):1.38(1H、brs)、2.97(2H、t、J=6.6Hz)、3.87(2H、t、J=6.6Hz)、7.16(1H、d、J=8.2Hz)、7.34(1H、dd、J=1.8、8.2Hz)、7.56(1H、d、J=1.8Hz)。
2−(4−ブロモ−2−クロロフェニル)エチルヨージド
1H−NMR(CDCl3)δ(ppm):3.22−3.28(2H、m)、3.32−3.38(2H、m)、7.12(1H、d、J=8.1Hz)、7.36(1H、dd、J=1.8、8.1Hz)、7.53(1H、d、J=2.1Hz)。
2−[2−(4−ブロモ−2−クロロフェニル)エチル]−2−[(tert−ブトキシカルボニル)アミノ]マロン酸ジエチル
1H−NMR(CDCl3)δ(ppm):1.26(6H、t、J=7.1Hz)、1.44(9H、s)、2.57(4H、s)、4.16−4.30(4H、m)、6.01(1H、s)、7.05(1H、d、J=8.1Hz)、7.30(1H、dd、J=1.8、8.4Hz)、7.49(1H、d、J=1.8Hz)。
[1,1−ビス(ヒドロキシメチル)−3−(4−ブロモ−2−クロロフェニル)プロピル]カルバミド酸tert−ブチルエステル
1H−NMR(CDCl3)δ(ppm):1.45(9H、s)、1.80−1.86(2H、m)、2.67−2.73(2H、m)、3.32(2H、brs)、3.63−3.69(2H、m)、3.87−3.93(2H、m)、5.10(1H、s)、7.11(1H、d、J=8.2Hz)、7.32(1H、dd、J=2.1、8.2Hz)、7.49(1H、d、J=1.9Hz)。
N−[1,1−ビス(アセトキシメチル)−3−(4−ブロモ−2−クロロフェニル)プロピル]アセタミド
1H−NMR(CDCl3)δ(ppm):2.00(3H、s)、2.10(6H、s)、2.12−2.16(2H、m)、2.66−2.72(2H、m)、4.36(4H、s)、5.75(1H、s)、7.10(1H、d、J=8.2Hz)、7.32(1H、dd、J=1.9、8.2Hz)、7.50(1H、d、J=1.9Hz)。
N−{1,1−ビス(アセトキシメチル)−3−[2−クロロ−4−(5,5−ジメチル−1,3,2−ジオキサボリナン−2−イル)フェニル]プロピル}アセタミド
1H−NMR(CDCl3)δ(ppm):1.01(6H、s)、1.99(3H、s)、2.09(6H、s)、2.12−2.18(2H、m)、2.71−2.77(2H、m)、3.76(4H、s)、4.38(4H、s)、5.71(1H、s)、7.21(1H、d、J=7.8Hz)、7.59(1H、d、J=7.5Hz)、7.75(1H、d、J=0.9Hz)。
N−[1,1−ビス(アセトキシメチル)−3−(4’−ブロモ−3−クロロ−2’−フルオロビフェニル−4−イル)プロピル]アセタミド
1H−NMR(CDCl3)δ(ppm):2.01(3H、s)、2.11(6H、s)、2.18−2.24(2H、m)、2.75−2.81(2H、m)、4.39(4H、s)、5.74(1H、s)、7.24−7.38(5H、m)、7.50(1H、s)。
2−[2−(4−ブロモフェニル)エチル]−2−メチルマロン酸ジエチル
MS(ESI)m/z:357、359[M+H]
1H−NMR(CDCl3)δ(ppm):1.26(6H、t、J=7.1Hz)、1.48(3H、s)、2.10−2.14(2H、m)、2.51−2.56(2H、m)、4.19(4H、q、J=7.1Hz)、7.05(2H、d、J=7.9Hz)、7.39(2H、d、J=7.9Hz)。
4−(4−ブロモフェニル)−2−エトキシカルボニル−2−メチル酪酸
1H−NMR(CDCl3)δ(ppm):1.29(3H、t、J=7.1Hz)、1.54(3H、s)、2.09−2.23(2H、m)、2.50−2.63(2H、m)、4.23(2H、q、J=6.7Hz)、7.05(2H、d、J=8.4Hz)、7.39(2H、d、J=8.4Hz)。
4−(4−ブロモフェニル)−2−メトキシカルボニルアミノ−2−メチル酪酸エチル
MS(ESI)m/z:358、360[M+H]
1H−NMR(CDCl3)δ(ppm):1.28(3H、t、J=7.1Hz)、1.59(3H、s)、2.06−2.11(1H、m)、2.30−2.38(1H、m)、2.52−2.62(2H、m)、3.65(3H、s)、4.14−4.22(2H、m)、5.68(1H、brs)、7.02(2H、d、J=8.4Hz)、7.37(2H、d、J=8.4Hz)。
2−アセタミド−4−(4−ブロモフェニル)−2−メチルブチル アセタート
MS(ESI)m/z:342、344[M+H]
1H−NMR(CDCl3)δ(ppm):1.36(3H、s)、1.89−1.96(1H、m)、1.94(3H、s)、2.09(3H、s)、2.18−2.26(1H、m)、2.51−2.58(2H、m)、4.15(1H、d、J=11.2Hz)、4.32(1H、d、J=11.2Hz)、5.36(1H、brs)、7.06(2H、d、J=8.3Hz)、7.38(2H、d、J=8.3Hz)。
2−アセタミド−4−[4−(5,5−ジメチル−1,3,2−ジオキサボリナン−2−イル)フェニル]−2−メチルブチル アセタート
1H−NMR(CDCl3)δ(ppm):1.01(6H、s)、1.37(3H、s)、1.87−1.97(1H、m)、1.91(3H、s)、2.09(3H、s)、2.16−2.26(1H、m)、2.61(2H、t、J=8.6Hz)、3.76(4H、s)、4.18(1H、d、J=11.1Hz)、4.33(1H、d、J=11.1Hz)、5.33(1H、s)、7.18(2H、d、J=7.5Hz)、7.71(2H、d、J=7.8Hz)。
2−アセタミド−4−(4’−ブロモ−2’−フルオロビフェニル−4−イル)−2−メチルブチル アセタート
1H−NMR(CDCl3)δ(ppm):1.39(3H、s)、1.92−2.03(1H、m)、1.94(3H、s)、2.10(3H、s)、2.26−2.34(1H、m)、2.65(2H、t、J=8.7Hz)、4.19(1H、d、J=11.1Hz)、4.36(1H、d、J=11.4Hz)、5.39(1H、s)、7.26−7.36(5H、m)、7.43(2H、dd、J=1.2、7.8Hz)。
4−(4−ブロモフェニル)−2−エトキシカルボニル−2−エチル酪酸
1H−NMR(CDCl3)δ(ppm):0.89(3H、t、J=7.5Hz)、1.32(3H、t、J=7.2Hz)、1.90−2.00(1H、m)、2.02−2.18(2H、m)、2.22−2.31(1H、m)、2.37−2.44(1H、m)、2.52−2.60(1H、m)、4.18−4.31(2H、m)、7.03(2H、d、J=8.4Hz)、7.39(2H、d、J=8.4Hz)。
4−(4−ブロモフェニル)−2−エチル−2−(メトキシカルボニルアミノ)酪酸エチル
MS(ESI)m/z:372、374[M+H]
1H−NMR(CDCl3)δ(ppm):0.76(3H、t、J=7.4Hz)、1.29(3H、t、J=7.3Hz)、1.71−1.80(1H、m)、2.01−2.08(1H、m)、2.24−2.39(2H、m)、2.53−2.62(1H、m)、2.64−2.73(1H、m)、3.64(3H、s)、4.09−4.25(2H、m)、5.81(1H、br.s)、7.01(2H、d、 J=8.2Hz)、7.37(2H、d、J=8.2Hz)。
2−アセタミド−2−エチル−4−(4−ブロモフェニル)ブチル アセタート
MS(ESI)m/z:356、358[M+H]
1H−NMR(CDCl3)δ(ppm):0.89(3H、t、J=7.6Hz)、1.75−1.85(2H、m)、1.91−1.99(1H、m)、1.95(3H、s)、2.07−2.15(1H、m)、2.09(3H、s)、2.48−2.54(2H、m)、4.27(1H、d、J=11.3Hz)、4.31(1H、d、J=11.3Hz)、5.23(1H、br.s)、7.05(2H、d、J=8.4Hz)、7.39(2H、d、J=8.4Hz)。
2−アセタミド−4−[4−(5,5−ジメチル−1,3,2−ジオキサボリナン−2−イル)フェニル]−2−エチルブチル アセタート
1H−NMR(CDCl3)δ(ppm):0.88(3H、t、J=7.5Hz)、1.01(6H、s)、1.70−2.18(4H、m)、1.93(3H、s)、2.08(3H、s)、2.56(2H、t、J=8.6Hz)、3.76(4H、s)、4.32(2H、s)、5.26(1H、s)、7.17(2H、d、J=7.5Hz)、7.71(2H、d、J=7.8Hz)。
2−アセタミド−4−(4’−ブロモ−2’−フルオロビフェニル−4−イル)−2−エチルブチル アセタート
1H−NMR(CDCl3)δ(ppm):0.91(3H、t、J=7.5Hz)、1.70−2.25(4H、m)、1.96(3H、s)、2.10(3H、s)、2.61(2H、t、J=8.5Hz)、4.30(2H、d、J=11.4Hz)、4.36(2H、d、J=11.4Hz)、7.25−7.36(5H、m)、7.43(2H、dd、J=1.5、8.2Hz)。
2−アミノ−2−{2−[4−(5−フェニルチオナフタレン−1−イル)フェニル]エチル}プロパン−1,3−ジオール塩酸塩
(1−1)N−{1,1−ビス(アセトキシメチル)−3−[4−(5−ベンジルオキシナフタレン−1−イル)フェニル]プロピル}アセタミドの合成
MS(ESI)m/z:554[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.88(3H、s)、2.05(6H、s)、2.05−2.10(2H、m)、2.62−2.66(2H、m)、4.23(2H、d、J=11.0Hz)、4.32(2H、d、J=11.0Hz)、5.34(2H、s)、7.11(1H、dd、J=2.7、5.7Hz)、7.31−7.46(10H、m)、7.54−7.58(3H、m)、7.68(1H、s)、8.26(1H、d、J=8.4Hz)。
MS(ESI)m/z:464[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.88(3H、s)、2.05(6H、s)、2.05−2.09(2H、m)、2.62−2.66(2H、m)、4.23(2H、d、J=11.0Hz)、4.32(2H、d、J=11.0Hz)、6.89(1H、dd、J=1.4、6.4Hz)、7.21−7.40(7H、m)、7.46−7.50(1H、m)、7.68(1H、s)、8.17(1H、d、J=8.4Hz)、10.15(1H、brs)。
1H−NMR(DMSO−d6)δ(ppm):1.90(3H、s)、2.07(6H、s)、2.07−2.12(2H、m)、2.66−2.70(2H、m)、4.25(2H、d、J=11.0Hz)、4.34(2H、d、J=11.1Hz)、7.38(2H、d、J=8.2Hz)、7.44(2H、d、J=8.2Hz)、7.62−7.76(4H、m)、7.86(1H、dd、J=7.3、8.2Hz)、7.95(1H、d、J=8.6Hz)、8.03(1H、d、J=8.4Hz)。
MS(ESI)m/z:430[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.87−1.92(2H、m)、2.70−2.74(2H、m)、3.57(4H、d、J=4.8Hz)、5.40(2H、t、J=4.8Hz)、7.20−7.53(11H、m)、7.63−7.67(1H、m)、7.73(1H、d、J=7.2Hz)、7.78(3H、brs)、7.87(1H、d、J=8.6Hz)、8.33(1H、d、J=8.5Hz)。
2−アミノ−2−(2−{4−[5−(4−メチルフェニルチオ)ナフタレン−1−イル]フェニル}エチル)プロパン−1,3−ジオール塩酸塩
(2−1)N−(1,1−ビス(アセトキシメチル)−3−{4−[5−(4−メチルフェニルチオ)ナフタレン−1−イル]フェニル}プロピル)アセタミドの合成
MS(ESI)m/z:444[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.87−1.92(2H、m)、2.27(3H、s)、2.70−2.74(2H、m)、3.57(4H、d、J=4.7Hz)、5.40(2H、t、J=4.9Hz)、7.16−7.20(4H、m)、7.37−7.48(6H、m)、7.58−7.66(2H、m)、7.79−7.83(4H、m)、8.32(1H、d、J=8.6Hz)。
2−アミノ−2−{2−[2’−フルオロ−4’−(フェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール塩酸塩
(3−1)N−(5−{2−[2’−フルオロ−4’−(フェニルチオ)ビフェニル−4−イル]エチル}−2,2−ジメチル−1,3−ジオキサン−5−イル)アセタミドの合成
1H−NMR(CDCl3)δ(ppm):1.43(6H、s)、2.02(3H、s)、2.07−2.13(2H、m)、2.55−2.61(2H、m)、3.69(2H、d、J=11.7Hz)、4.00(2H、d、J=11.7Hz)、5.79(1H、s)、7.02(1H、d、J=11.1Hz)、7.10(1H、d、J=9.6Hz)、7.23−7.47(10H、m)。
(468mg)をメタノール(6mL)に溶解させ、濃塩酸(3mL)を加え、70℃にて3.5時間攪拌した。反応液を濃縮し、残渣の粗結晶をジイソプロピルエーテルで縣濁濾取することにより、表題化合物329mgを白色結晶として得た。
MS(ESI)m/z:398[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.79−1.85(2H、m)、2.63−2.69(2H、m)、3.54(4H、d、J=4.5Hz)、5.41(2H、t、J=5.0Hz)、7.13−7.17(2H、m)、7.32(2H、d、J=8.4Hz)、7.44−7.53(8H、m)、7.83(3H、brs)。
2−アミノ−2−{2−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール
(4−1)N−(5−{2−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]エチル}−2,2−ジメチル−1,3−ジオキサン−5−イル)アセタミドの合成
1H−NMR(CDCl3)δ(ppm):1.43(6H、s)、2.02(3H、s)、2.05−2.12(2H、m)、2.38(3H、s)、2.55−2.60(2H、m)、3.69(2H、d、J=12.0Hz)、3.99(2H、d、J=12.0Hz)、5.74(1H、s)、6.93(1H、d、J=11.1Hz)、7.03(1H、d、J=9.9Hz)、7.18−7.42(9H、m)。
MS(ESI)m/z:412[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.30(2H、brs)、1.49−1.54(2H、m)、2.35(3H、s)、2.60−2.65(2H、m)、3.19−3.29(4H、m)、4.47(2H、brs)、7.04(2H、d、J=9.9Hz)、7.29(4H、m)、7.39−7.48(5H、m)。
2−アミノ−2−{2−[2’−フルオロ−4’−(3−メチルフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール塩酸塩
(5−1)N−[5−{2−[2’−フルオロ−4’−(3−メチルフェニルチオ)ビフェニル−4−イル]エチル)−2,2−ジメチル−1,3−ジオキサン−5−イル}アセタミドの合成
1H−NMR(CDCl3)δ(ppm):1.43(6H、s)、2.02(3H、s)、2.07−2.13(2H、m)、2.35(3H、s)、2.55−2.61(2H、m)、3.70(2H、d、J=11.9Hz)、4.00(2H、d、J=11.9Hz)、5.78(1H、s)、7.00(1H、d、J=11.8Hz)、7.07−7.10(1H、m)、7.23−7.43(9H、m)。
MS(ESI)m/z:412[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.79−1.85(2H、m)、2.33(3H、s)、2.63−2.68(2H、m)、3.53−3.54(4H、m)、5.39(2H、t、J=4.7Hz)、7.10−7.14(2H、m)、7.23−7.49(9H、m)、7.81(3H、brs)。
2−アミノ−2−{2−[4’−(4−エチルフェニルチオ)−2’−フルオロ−ビフェニル−4−イル]エチル}プロパン−1,3−ジオールの合成
MS(ESI)m/z:426[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.20(3H、t、J=7.5Hz)、1.29(2H、brs)、1.49−1.54(2H、m)、2.60−2.68(4H、m)、3.21−3.29(4H、m)、4.46(2H、t、J=5.1Hz)、7.05−7.08(2H、m)、7.09−7.34(4H、m)、7.40−7.49(5H、m)。
2−アミノ−2−{2−[2’−フルオロ−4’−(3−フルオロフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオールの合成
MS(ESI)m/z:416[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.30(2H、brs)、1.50−1.56(2H、m)、2.61−2.67(2H、m)、3.19−3.30(4H、m)、4.47(2H、t、J=5.4Hz)、7.23−7.33(7H、m)、7.44−7.55(4H、m)。
2−アミノ−2−{2−[2’−フルオロ−4’−(2−フルオロ−4−メチルフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオールの合成
MS(ESI)m/z:430[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.29(2H、brs)、1.49−1.55(2H、m)、2.38(3H、s)、2.60−2.65(2H、m)、3.19−3.32(4H、m)、4.46(2H、t、J=5.1Hz)、7.01−7.08(2H、m)、7.15(1H、d、J=7.2Hz)、7.25−7.29(3H、m)、7.40−7.51(4H、m)。
2−アミノ−2−{2−[2’−フルオロ−4’−(4−フルオロフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオールの合成
MS(ESI)m/z:416[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.29(2H、brs)、1.49−1.55(2H、m)、2.60−2.66(2H、m)、3.19−3.29(4H、m)、4.46(2H、t、J=5.2Hz)、7.07−7.26(2H、m)、7.29−7.60(9H、m)。
2−アミノ−2−{2−[4’−(4−クロロフェニルチオ)−2’−フルオロビフェニル−4−イル]エチル}プロパン−1,3−ジオールの合成
MS(ESI)m/z:432[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.31(2H、brs)、1.50−1.55(2H、m)、2.61−2.66(2H、m)、3.20−3.28(4H、m)、4.46(2H、brs)、7.16−7.30(4H、m)、7.43−7.55(7H、m)。
2−アミノ−2−{2−[2’−フルオロ−4’−(5−メチル−2−チエニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオールの合成
MS(ESI)m/z:418[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.33(2H、brs)、1.49−1.55(2H、m)、2.50(3H、s)、2.60−2.65(2H、m)、3.20−3.24(4H、m)、4.46(2H、brs)、6.94(1H、d、J=3.3Hz)、7.00−7.05(2H、m)、7.26−7.49(6H、m)。
2−アミノ−2−{2−[2’−フルオロ−4’−(4−トリフルオロメチルフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオールの合成
MS(ESI)m/z:466[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.32(2H、brs)、1.51−1.56(2H、m)、2.62−2.68(2H、m)、3.22−3.29(4H、m)、4.48(2H、brs)、7.30−7.38(3H、m)、7.44−7.52(5H、m)、7.61(1H、t、J=8.2Hz)、7.74(2H、d、J=8.4Hz)。
2−アミノ−2−{2−[4’−(2,4−ジメチルフェニルチオ)−2’−フルオロビフェニル−4−イル]エチル}プロパン−1,3−ジオール
(13−1)N−(5−{2−[4’−(2,4−ジメチルフェニルチオ)−2’−フルオロビフェニル−4−イル]エチル}−2,2−ジメチル−1,3−ジオキサン−5−イル)アセタミドの合成
1H−NMR(CDCl3)δ(ppm):1.43(6H、s)、2.01(3H、s)、2.07−2.12(2H、m)、2.35(3H、s)、2.36(3H、s)、2.54−2.60(2H、m)、3.69(2H、d、J=12.0Hz)、3.99(2H、d、J=12.0Hz)、5.79(1H、s)、6.78(1H、dd、J=1.8、11.4Hz)、6.91(1H、dd、J=1.8、8.1Hz)、7.04(1H、d、J=7.8Hz)、7.14(1H、s)、7.21−7.28(3H、m)、7.38−7.41(3H、m)。
MS(ESI)m/z:426[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.40−1.82(4H、m)、2.32(3H、s)、2.33(3H、s)、2.59−2.65(2H、m)、3.21−3.29(4H、m)、4.48(2H、brs)、6.88(1H、d、J=3.7Hz)、6.92(1H、s)、7.13(1H、d、J=7.8Hz)、7.27(3H、d、J=7.4Hz)、7.39−7.49(4H、m)。
2−アミノ−2−{2−[2’−フルオロ−4’−(3−メトキシフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール
(14−1)N−(5−{2−[2’−フルオロ−4’−(3−メトキシフェニルチオ)ビフェニル−4−イル]エチル}−2,2−ジメチル−1,3−ジオキサン−5−イル)アセタミドの合成
1H−NMR(CDCl3)δ(ppm):1.43(6H、s)、2.02(3H、s)、2.08−2.13(2H、m)、2.55−2.61(2H、m)、3.70(2H、d、J=11.7Hz)、3.79(3H、s)、4.00(2H、d、J=12.0Hz)、5.76(1H、s)、6.80−6.88(1H、m)、6.98−7.14(4H、m)、7.23−7.33(4H、m)、7.42(2H、dd、J=1.5、8.1Hz)。
MS(ESI)m/z:428[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.55−1.61(2H、m)、2.61−2.66(2H、m)、3.26−3.33(4H、m)、3.76(3H、s)、4.64(2H、brs)、6.92−7.08(3H、m)、7.15−7.58(8H、m)。
2−アミノ−2−{2−[2’−フルオロ−4’−(4−メトキシフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール塩酸塩
(15−1)N−(5−{2−[2’−フルオロ−4’−(4−メトキシフェニルチオ)ビフェニル−4−イル]エチル}−2,2−ジメチル−1,3−ジオキサン−5−イル)アセタミドの合成
1H−NMR(CDCl3)δ(ppm):1.43(6H、s)、2.02(3H、s)、2.07−2.12(2H、m)、2.54−2.60(2H、m)、3.69(2H、d、J=11.9Hz)、3.85(3H、s)、3.99(2H、d、J=11.9Hz)、5.74(1H、s)、6.80−6.86(1H、m)、6.93−6.98(3H、m)、7.21−7.26(3H、m)、7.40(2H、dd、J=1.3、8.1Hz)、7.46−7.49(2H、m)。
MS(ESI)m/z:428[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.75−1.81(2H、m)、2.59−2.65(2H、m)、3.50(4H、d、J=4.3Hz)、3.80(3H、s)、5.36(2H、brs)、6.92−6.96(2H、m)、7.05(2H、d、J=6.6Hz)、7.28(2H、d、J=8.2Hz)、7.41−7.43(3H、m)、7.50(2H、d、J=8.8Hz)、7.69(3H、brs)。
2−アミノ−2−{2−[4’−(3,4−ジメチルフェニルチオ)−2’−フルオロビフェニル−4−イル]エチル}プロパン−1,3−ジオール塩酸塩
(16−1)N−(5−{2−[4’−(3,4−ジメチルフェニルチオ)−2’−フルオロビフェニル−4−イル]エチル}−2,2−ジメチル−1,3−ジオキサン−5−イル)アセタミドの合成
1H−NMR(CDCl3)δ(ppm):1.43(6H、s)、2.02(3H、s)、2.07−2.12(2H、m)、2.26(3H、s)、2.28(3H、s)、2.55−2.60(2H、m)、3.69(2H、d、J=12.0Hz)、3.99(2H、d、J=11.7Hz)、5.76(1H、s)、6.92(1H、d、J=11.1Hz)、7.02(1H、dd、J=1.8、9.9Hz)、7.05−7.29(6H、m)、7.41(2H、dd、J=1.5、8.1Hz)。
MS(ESI)m/z:426[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.76−1.82(2H、m)、2.23(3H、s)、2.24(3H、s)、2.60−2.66(2H、m)、3.51(4H、d、J=4.4Hz)、5.38(2H、brs)、7.01(2H、d、J=9.9Hz)、7.24−7.33(5H、m)、7.41−7.46(3H、m)、7.77(3H、brs)。
2−アミノ−2−{2−[2’−フルオロ−4’−(4−イソプロピルフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール塩酸塩
(17−1)N−(5−{2−[2’−フルオロ−4’−(4−イソプロピルフェニルチオ)ビフェニル−4−イル]エチル}−2,2−ジメチル−1,3−ジオキサン−5−イル)アセタミドの合成
1H−NMR(CDCl3)δ(ppm):1.27(6H、d、J=6.9Hz)、1.43(6H、s)、2.02(3H、s)、2.07−2.13(2H、m)、2.55−2.60(2H、m)、2.93(1H、sept、J=6.9Hz)、3.69(2H、d、J=12.0Hz)、4.00(2H、d、J=12.0Hz)、5.76(1H、s)、6.96(1H、dd、J=1.8、11.1Hz)、7.05(1H、dd、J=1.8、8.1Hz)、7.22−7.32(5H、m)、7.41(4H、d、J=8.1Hz)。
MS(ESI)m/z:440[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.20(6H、d、J=6.9Hz)、1.77−1.83(2H、m)、2.61−2.66(2H、m)、2.91(1H、sept、J=6.9Hz)、3.52(4H、d、J=4.6Hz)、5.39(2H、t、J=4.6Hz)、7.05−7.09(2H、m)、7.28−7.35(4H、m)、7.41−7.46(5H、m)、7.83(3H、brs)。
2−アミノ−2−{2−[3−クロロ−2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール
(18−1)N−[1,1−ビス(アセトキシメチル)−3−[3−クロロ−2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]プロピル]アセタミドの合成
1H−NMR(CDCl3)δ(ppm):2.00(3H、s)、2.10(6H、s)、2.17−2.22(2H、m)、2.38(3H、s)、2.73−2.79(2H、m)、4.39(4H、s)、5.77(1H、s)、6.91(1H、dd、J=1.8、11.4Hz)、7.02(1H、dd、J=1.5、9.9Hz)、7.20−7.32(5H、m)、7.40(2H、d、J=8.1Hz)、7.48(1H、s)。
MS(ESI)m/z:446[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.29(2H、brs)、1.47−1.53(2H、m)、2.35(3H、s)、2.72−2.77(2H、m)、3.21−3.30(4H、m)、4.49(2H、t、J=4.7Hz)、7.01−7.06(2H、m)、7.30(2H、d、J=8.0Hz)、7.38−7.52(6H、m)。
2−アミノ−2−{2−[2’−フルオロ−4’−(4−メチルフェノキシ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール
(19−1)N−[1,1−ビス(アセトキシメチル)−3−(2’−フルオロ−4’−ヒドロキシビフェニル−4−イル)プロピル]アセタミドの合成
1H−NMR(CDCl3)δ(ppm):2.04(3H、s)、2.11(6H、s)、2.29−2.34(2H、m)、2.61−2.67(2H、m)、4.38(4H、s)、6.06(1H、s)、6.64−6.71(2H、m)、7.10−7.27(3H、m)、7.38(2H、dd、J=1.2、8.1Hz)、8.42(1H、brs)。
1H−NMR(CDCl3)δ(ppm):1.97(3H、s)、2.09(6H、s)、2.22−2.28(2H、m)、2.35(3H、s)、2.63−2.68(2H、m)、4.37(4H、s)、5.80(1H、s)、6.72−6.79(2H、m)、6.97(2H、d、J=8.4Hz)、7.16−7.44(7H、m)。
MS(ESI)m/z:396[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.72−1.78(2H、m)、2.36(3H、s)、2.67−2.72(2H、m)、3.54(2H、d、J=10.5Hz)、3.63(2H、d、J=10.8Hz)、6.72−6.83(2H、m)、6.98(2H、d、J=8.7Hz)、7.18(2H、d、J=8.4Hz)、7.25−7.28(2H、m)、7.34(1H、t、J=8.6Hz)、7.44(2H、dd、J=1.5、8.1Hz)。
(5−{4−[3−アミノ−4−ヒドロキシ−3−(ヒドロキシメチル)ブチル]フェニル}−2−チエニル)(4−メチルフェニル)ケトン
(20−1)N−(5−{2−[4−(5−ホルミル−2−チエニル)フェニル]エチル}−2,2−ジメチル−1,3−ジオキサン−5−イル)アセタミドの合成
1H−NMR(CDCl3)δ(ppm):1.44(6H、s)、2.05(3H、s)、2.08−2.12(2H、m)、2.55−2.61(2H、m)、3.70(2H、d、J=11.7Hz)、3.98(2H、d、J=11.7Hz)、5.78(1H、s)、7.25(2H、d、J=8.7Hz)、7.37(1H、d、J=3.3Hz)、7.58(2H、d、J=8.4Hz)、7.73(1H、d、J=3.9Hz)、9.88(1H、s)。
1H−NMR(CDCl3)δ(ppm):1.42(6H、s)、2.02−2.09(5H、m)、2.36(3H、s)、2.50−2.56(2H、m)、3.65−3.69(3H、m)、3.97(2H、d、J=12.0Hz)、5.74(1H、s)、6.00(1H、d、J=3.6Hz)、6.83(1H、d、J=3.6Hz)、7.08(1H、d、J=3.6Hz)、7.13−7.26(4H、m)、7.37(2H、d、J=8.1Hz)、7.44(2H、d、J=8.1Hz)。
1H−NMR(CDCl3)δ(ppm):1.44(6H、s)、2.04(3H、s)、2.06−2.12(2H、m)、2.45(3H、s)、2.55−2.60(2H、m)、3.70(2H、d、J=12.0Hz)、3.98(2H、d、J=12.0Hz)、5.83(1H、s)、7.22−7.31(5H、m)、7.57−7.60(3H、m)、7.79(2H、d、J=8.1Hz)。
MS(ESI)m/z:396[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.61−1.67(2H、m)、2.42(3H、s)、2.62−2.68(2H、m)、3.32(4H、brs)、4.83(4H、brs)、7.32(2H、t、J=8.1Hz)、7.39(2H、t、J=7.8Hz)、7.63(1H、d、J=4.2Hz)、7.71−7.79(5H、m)。
2−アミノ−4−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]−2−メチルブタノール塩酸塩
(21−1)2−アセタミド−4−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]−2−メチルブチル アセタートの合成
1H−NMR(CDCl3)δ(ppm):1.39(3H,s)、1.92−2.04(1H、m)、1.92(3H、s)、2.10(3H、s)、2.18−2.34(1H、m)、2.38(3H、s)、2.64(2H、t、J=8.4Hz)、4.19(1H、d、J=11.1Hz)、4.35(1H、d、J=11.1Hz)、5.35(1H、s)、6.93(1H、dd、J=1.8、11.1Hz)、7.03(1H、dd、J=1.8、8.1Hz)、7.19−7.32(6H、m)、7.38−7.43(3H、m)。
MS(ESI)m/z:396[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.22(3H、s)、1.76−1.91(2H、m)、2.35(3H、s)、2.65(2H、t、J=8.7Hz)、3.41−3.50(2H、m)、5.50(1H、s)、7.03−7.07(2H、m)、7.29−7.32(4H、m)、7.41−7.49(5H、m)、7.84(3H、brs)。
2−アミノ−2−エチル−4−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]ブタノール
(22−1)2−アセタミド−2−エチル−4−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]ブチル アセタートの合成
1H−NMR(CDCl3)δ(ppm):0.90(3H、t、J=7.5Hz)、1.74−2.14(4H、m)、1.94(3H、s)、2.10(3H、s)、2.38(3H、s)、2.60(2H、t、J=8.4Hz)、4.30(1H、d、J=11.4Hz)、4.35(1H、d、J=11.4Hz)、5.22(1H、s)、6.94(1H、d、J=11.1Hz)、7.02−7.05(1H、m)、7.19−7.43(9H、m)。
MS(ESI)m/z:410[M+H]
1H−NMR(DMSO−d6)δ(ppm):0.82(3H、t、J=7.5Hz)、1.21(2H、brs)、1.34(2H、q、J=7.5Hz)、1.50(2H、t、J=8.6Hz)、2.35(3H、s)、2.55−2.62(2H、m)、3.19(2H、d、J=4.5Hz)、4.47(1H、t、J=4.5Hz)、7.03−7.06(2H、m)、7.26−7.30(4H、m)、7.40−7.48(5H、m)。
2−アミノ−4−[2’−フルオロ−4’−(フェニルチオ)ビフェニル−4−イル]−2−(ホスホリルオキシメチル)ブタノール
(23−1)2−アミノ−2−[2−(4’−ブロモ−2’−フルオロビフェニル−4−イル)エチル]プロパン−1,3−ジオールの合成
1H−NMR(DMSO−d6)δ(ppm):1.28(2H、s)、1.50−1.55(2H、m)、2.61−2.67(2H、m)、3.25(4H、dd、J=10.8、15.4Hz)、4.49(2H、brs)、7.30(2H、d、J=8.1Hz)、7.43−7.52(4H、m)、7.64(1H、d、J=11.0Hz)。
1H−NMR(CDCl3)δ(ppm):1.49(18H、s)、1.87−2.02(2H、m)、2.04(3H、s)、2.70(2H、t、J=8.6Hz)、3.86−4.02(3H、m)、4.36(1H、d、J=8.9Hz)、7.26−7.44(7H、m)。
1H−NMR(CDCl3)δ(ppm):1.49(18H、s)、1.58−1.95(2H、m)、2.02(3H、s)、2.69(2H、t、J=8.6Hz)、3.87−4.03(3H、m)、4.36(1H、d、J=8.7Hz)、7.04−7.12(2H、m)、7.24−7.47(10H、m)。
MS(ESI)m/z:478[M+H]
1H−NMR(CD3OD)δ(ppm):1.94−2.05(2H、m)、2.68−2.80(2H、m)、3.73(2H、s)、3.93−4.08(2H、m)、7.03−7.06(1H、m)、7.13(1H、d、J=8.4Hz)、7.34−7.49(10H、m)。
2−アミノ−4−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]−2−(ホスホリルオキシメチル)ブタノール
(24−1)4−{2−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]エチル}−4−ジ(tert−ブチル)ホスホリルオキシメチル−2−メチル−2−オキサゾリンの合成
1H−NMR(CDCl3)δ(ppm):1.48(18H、s)、1.77−2.10(2H、m)、2.01(3H、s)、2.38(3H、s)、2.69(2H、t、J=8.7Hz)、3.89(1H、dd、J=4.8、10.2Hz)、3.97(1H、dd、J=5.1、9.9Hz)、4.01(1H、d、J=8.7Hz)、4.35(1H、d、J=8.7Hz)、6.93(1H、d、J=12.6Hz)、7.03(1H、d、J=9.6Hz)、7.18−7.32(5H、m)、7.38−7.43(4H、m)。
MS(ESI)m/z:492[M+H]
1H−NMR(CD3OD)δ(ppm):1.98−2.08(2H、m)、2.38(3H、s)、2.68−2.82(2H、m)、3.72(2H、s)、3.94−4.10(2H、m)、6.91(1H、d、J=11.4Hz)、7.05(1H、d、J=8.1Hz)、7.24−7.45(9H、m)。
2−アミノ−4−[2’−フルオロ−4’−(3−メチルフェニルチオ)ビフェニル−4−イル]−2−(ホスホリルオキシメチル)ブタノール
(25−1)4−{2−[2’−フルオロ−4’−(3−メチルフェニルチオ)ビフェニル−4−イル]エチル}−4−ジ(tert−ブチル)ホスホリルオキシメチル−2−メチル−2−オキサゾリンの合成
1H−NMR(CDCl3)δ(ppm):1.49(18H、s)、1.64−2.10(5H、m)、2.35(3H、s)、2.69(2H、t、J=8.7Hz)、3.89(1H、dd、J=4.5、9.9Hz)、3.98(1H、dd、J=5.1、9.9Hz)、4.01(1H、d、J=8.7Hz)、4.36(1H、d、J=9.0Hz)、7.00(1H、d、J=12.9Hz)、7.09(1H、d、J=8.1Hz)、7.14−7.35(7H、m)、7.43(2H、dd、J=1.5、7.8Hz)。
MS(ESI)m/z:492[M+H]
1H−NMR(CD3OD)δ(ppm):1.97−2.05(2H、m)、2.34(3H、s)、2.68−2.82(2H、m)、3.72(2H、s)、3.92−4.10(2H、m)、6.97(1H、d、J=11.4Hz)、7.09(1H、d、J=9.9Hz)、7.18−7.47(9H、m)。
2−アミノ−4−[2’−フルオロ−4’−(4−メチルフェノキシ)ビフェニル−4−イル]−2−(ホスホリルオキシメチル)ブタノール
(26−1)4−{2−[2’−フルオロ−4’−(4−メチルフェノキシ)ビフェニル−4−イル]エチル}−4−ジ(tert−ブチル)ホスホリルオキシメチル−2−メチル−2−オキサゾリンの合成
1H−NMR(CDCl3)δ(ppm):1.49(18H、s)、1.80−2.10(2H、m)、2.02(3H、s)、2.36(3H、s)、2.69(2H、t、J=8.6Hz)、3.90(1H、dd、J=4.5、9.9Hz)、3.98(1H、dd、J=4.8、9.9Hz)、4.02(1H、d、J=8.4Hz)、4.36(1H、d、J=8.7Hz)、6.72−6.82(2H、m)、6.96−6.99(2H、m)、7.17−7.44(7H、m)。
MS(ESI)m/z:476[M+H]
1H−NMR(CD3OD)δ(ppm):1.96−2.08(2H、m)、2.35(3H、s)、2.64−2.80(2H、m)、3.72(2H、s)、3.95−4.08(2H、m)、6.71−6.83(2H、m)、6.96(2H、d、J=8.4Hz)、7.22(2H、d、J=8.4Hz)、7.31−7.45(5H、m)。
2−アミノ−4−[3−クロロ−2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]−2−(ホスホリルオキシメチル)ブタノール
(27−1)2−アミノ−2−[2−(4’−ブロモ−3−クロロ−2’−フルオロビフェニル−4−イル)エチル]プロパン−1,3−ジオール塩酸塩の合成
1H−NMR(DMSO−d6)δ(ppm):1.80−1.85(2H、m)、2.77−2.83(2H、m)、3.57(4H、d、J=4.7Hz)、5.42(2H、t、J=4.8Hz)、7.48−7.53(4H、m)、7.60(1H、s)、7.68(1H、d、J=10.1Hz)7.91(3H、brs)。
1H−NMR(CDCl3)δ(ppm):1.49(18H、s)、1.85−1.95(2H、m)、2.03(3H、s)、2.73−2.85(2H、m)、3.92(1H、dd、J=4.8、9.9Hz)、3.99(1H、dd、J=4.8、9.9Hz)、4.11(1H、d、J=9.0Hz)、4.38(1H、d、J=8.7Hz)、7.24−7.37(5H、m)、7.49(1H、s)。
1H−NMR(CDCl3)δ(ppm):1.49(18H、s)、1.85−1.95(2H、m)、2.03(3H、s)、2.39(3H、s)、2.72−2.83(2H、m)、3.92(1H、dd、J=4.8、9.9Hz)、3.99(1H、dd、J=4.8、9.9Hz)、4.12(1H、d、J=8.7Hz)、4.39(1H、d、J=8.9Hz)、6.93(1H、d、J=12.7Hz)、7.04(1H、d、J=8.2Hz)、7.20−7.42(7H、m)、7.49(1H、s)。
MS(ESI)m/z:526[M+H]
1H−NMR(CD3OD)δ(ppm):1.93−2.02(2H、m)、2.39(3H、s)、2.85−2.91(2H、m)、3.68−3.82(2H、m)、3.95−4.10(2H、m)、6.91(1H、d、J=11.1Hz)、7.04(1H、d、J=8.4Hz)、7.27(2H、d、J=7.8Hz)、7.35−7.42(5H、m)、7.53(1H、s)。
2−アミノ−2−(2−{4−[5−(3−メチルフェニルチオ)ナフタレン−1−イル]フェニル}エチル)プロパン−1,3−ジオール
(28−1)N−(1,1−ビス(アセトキシメチル)−3−{4−[5−(3−メチルフェニルチオ)ナフタレン−1−イル]フェニル}プロピル)アセタミドの合成
の合成
MS(ESI)m/z:444[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.63−1.68(2H、m)、2.25(3H、s)、2.68−2.72(2H、m)、3.30−3.37(4H、m)、4.64(2H、brs)、6.96(1H、d、J=7.8Hz)、7.06(1H、d、J=7.6Hz)、7.15(1H、s)、7.20(1H、t、J=7.7Hz)、7.36(2H、d、J=8.2Hz)、7.39(2H、d、J=8.2Hz)、7.47−7.51(2H、m)、7.64(1H、dd、J=7.3、8.4Hz)、7.68(1H、d、J=7.1Hz)、7.86(1H、d、J=7.1Hz)、8.32(1H、d、J=8.3Hz)。
2−アミノ−2−{2−[2’−フルオロ−4’−(4−メチルフェニルカルボニル)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール塩酸塩
MS(ESI)m/z:408[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.82−1.88(2H、m)、2.43(3H、s)、2.66−2.72(2H、m)、3.55(4H、d、J=4.8Hz)、5.43(2H、t、J=4.8Hz)、7.38(2H、d、J=8.1Hz)、7.41(2H、d、J=7.8Hz)、7.57−7.63(4H、m)、7.69−7.73(3H、m)、7.90(3H、brs)。
2−アミノ−4−[2’−フルオロ−4’−(4−メチルフェニルカルボニル)ビフェニル−4−イル]−2−(ホスホリルオキシメチル)ブタノール
(30−1)4−{2−[2’−フルオロ−4’−(4−メチルフェニルカルボニル)ビフェニル−4−イル]エチル}−4−ジ(tert−ブチル)ホスホリルオキシメチル−2−メチル−2−オキサゾリンの合成
1H−NMR(CDCl3)δ(ppm):1.49(18H、s)、1.70−1.90(2H、m)、2.03(3H、s)、2.46(3H、s)、2.72(2H、t、J=9.0Hz)、3.87−4.00(2H、m)、4.03(1H、d、J=8.4Hz)、4.37(1H、d、J=8.4Hz)、7.27−7.32(4H、m)、7.51−7.64(5H、m)、7.75(2H、d、J=7.8Hz)。
MS(ESI)m/z:488[M+H]
1H−NMR(CD3OD)δ(ppm):2.01−2.06(2H、m)、2.46(3H、s)、2.44−2.81(2H、m)、3.74(2H、s)、3.92−4.12(2H、m)、7.37−7.42(4H、m)、7.56−7.68(5H、m)、7.73(2H、d、J=8.4Hz)。
2−アミノ−2−{2−[4−(3−ベンジルオキシフェニルチオ)−2−クロロフェニル]エチル}プロパン−1,3−ジオール塩酸塩の合成
(1−1)N−{1,1−ビス(アセトキシメチル)−3−[2−クロロ−4−(3−ヒドロキシフェニルチオ)フェニル]プロピル}アセタミドの合成
1H−NMR(DMSO−d6)δ(ppm):1.84(3H、s)、1.92−1.97(2H、m)、2.02(6H、s)、2.62−2.66(2H、m)、4.20(2H、d、J=11.0Hz)、4.28(2H、d、J=11.1Hz)、6.70−6.78(3H、m)、7.18−7.32(4H、m)、7.68(1H、s)、9.76(1H、brs)。
MS(ESI)m/z:444[M+H]
1H−NMR(DMSO−d6)δ(ppm):1.77−1.81(2H、m)、2.72−2.76(2H、m)、3.56(4H、s)、5.10(2H、s)、5.40(2H、brs)、6.90−7.01(3H、m)、7.25(1H、dd、J=J=1.5、8.0Hz)、7.30−7.41(8H、m)、7.91(3H、brs)。
本発明化合物を20%シクロデキストリン(日本食品化工社製)に溶解又は懸濁させて、0.001〜10mg/kg体重の用量で、7〜10週齢の雄性BALB/cAnNCrjマウス(日本チャールス・リバー)に腹腔内投与した。本発明化合物の投与24時間後、エーテル麻酔下にマウスの後大静脈から、ヘパリンナトリウム(ノボ・ノルディスク社製)で処理したツベルクリン用シリンジ(テルモ社製)を用いて、末梢血を約0.3ml採取した。0.1mlの血液を自動溶血処理装置(TQ−Prep、ベックマン・コールター社製)を用いて溶血した後、フローサイトメーター(CYTOMICS FC 500、ベックマン・コールター社製)を用い、既知数の標準粒子であるFlow−CountTMFluorospheres(ベックマン・コールター社製)を内部標準として、レーザー光の前方及び側方散乱を指標としたゲーティング法でリンパ球数を測定した。ビークル群のリンパ球数を100%としたときに、それを50%低下させる用量を算出し、ED50値(mg/kg体重)とした。
雄性Sprague−Dawley(IGS)ラットにネンブタール(大日本製薬社製)を腹腔内投与することで麻酔した後、テレメトリー送信器(TL11M2−C50−PTX、データサイエンスインターナショナル社製)に接続している圧センサーを腹部大動脈内に挿入し、送信器を腹部皮下に留置した。血圧・心拍数のデータは受信器(RPC−1、データサイエンスインターナショナル社製)を介して解析ソフト(Dataquest A.R.T.、データサイエンス社)により記録した。術後10日から2週間経過後に心拍数のサーカデイアンリズムが回復したことを確認し、実験に供した。本発明化合物は、0.5%ヒドロキシプロピルメチルセルロース(信越化学工業製)に懸濁させて、経口投与した。心拍数は投与前24時間から投与後72時間まで測定した。実施例4で得られた化合物は、投与量10mg/kg体重までラットの心拍数に影響を与えなかった。
雄性Sprague−Dawley(IGS)ラットにネンブタール(大日本製薬社製)を腹腔内投与することで麻酔した後、背位に固定する。四肢に電極を装着し、心電図アンプ(AC−601G、日本光電社製)を用いて標準四肢第II誘導法にて心電図を計測する。心電図波をトリガーとして瞬時心拍計ユニット(AT−601G、日本光電社製)より心拍数を計数する。被験化合物は、20%シクロデキストリン(日本食品化工社製)に溶解させて、0.001〜10mg/kg体重の用量で、30秒間かけて静脈内投与する。心拍数は、投与前、投与後1、2、3、4、5、10及び15分に測定する。
本出願は、日本で出願された特願2006−126102を基礎としており、その内容は本明細書にすべて包含されるものである。
Claims (13)
- 下記一般式(I)
(式中、R1は水素原子又はP(=O)(OH)2、R2は水酸基で置換されていても良いか又はハロゲン原子で置換されていても良い炭素数1〜4のアルキル、R3は水素原子;ハロゲン原子;シアノ;ハロゲン原子で置換されていても良い炭素数1〜4のアルキル;又はハロゲン原子で置換されていても良い炭素数2〜5のアシル、Xは酸素原子、硫黄原子、カルボニル又はNR4(R4は水素原子又は炭素数1〜4のアルキル)、Ar1は置換されていても良いアリーレン又は置換されていても良いヘテロアリーレン、Ar2は置換されていても良いアリール又は置換されていても良いヘテロアリールを示す。ただし、Xが酸素原子、Ar1がフェニレンかつAr2がフェニルのとき、Ar2のフェニルは置換されている。)で表される2−アミノブタノール化合物、若しくはその製薬上許容しうる酸付加塩、又はそれらの水和物、若しくは溶媒和物。 - Xが硫黄原子である請求項1に記載の2−アミノブタノール化合物、若しくはその製薬上許容しうる酸付加塩、又はそれらの水和物、若しくは溶媒和物。
- R3が水素原子又はハロゲン原子である請求項1又は2に記載の2−アミノブタノール化合物、若しくはその製薬上許容しうる酸付加塩、又はそれらの水和物、若しくは溶媒和物。
- Ar1が置換されていても良いアリーレンである請求項1〜3のいずれか1項に記載の2−アミノブタノール化合物、若しくはその製薬上許容しうる酸付加塩、又はそれらの水和物、若しくは溶媒和物。
- Ar2が置換されていても良いアリールである請求項1〜4のいずれか1項に記載の2−アミノブタノール化合物、若しくはその製薬上許容しうる酸付加塩、又はそれらの水和物、若しくは溶媒和物。
- 一般式(I)の化合物が以下のa、bのいずれかである請求項1〜6のいずれか1項に記載の化合物、若しくはその製薬上許容しうる酸付加塩、又はそれらの水和物、若しくは溶媒和物。
a.2−アミノ−2−{2−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール
b.2−アミノ−4−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]−2−(ホスホリルオキシメチル)ブタノール - 2−アミノ−2−{2−[2’−フルオロ−4’−(4−メチルフェニルチオ)ビフェニル−4−イル]エチル}プロパン−1,3−ジオール、又はその塩酸塩。
- 請求項1〜8のいずれか1項に記載の化合物及び製薬上許容しうる担体を含有する医薬組成物。
- 自己免疫疾患の治療又は予防;器官又は組織の移植に対する急性拒絶反応又は慢性拒絶反応の予防又は抑制;骨髄移植による移植片対宿主(GvH)病の治療又は予防;アレルギー性疾患の治療又は予防のために用いられる請求項9に記載の医薬組成物。
- 一般式(II−4)で表される化合物の製造方法であって、一般式(II−1)で表される脱離基Xcを有するベンゼン化合物と一般式(II−2)で表されるベンゼンチオールとを縮合させ、又は一般式(II−1’)で表されるチオール化合物と一般式(II−2’)で表される脱離基Xcを有するベンゼン化合物とを縮合させて、一般式(II−3)で表される化合物を得た後、脱保護を行うことを特徴とする製造方法。
(式中、R8は保護されていても良い水酸基で置換されていても良いか又はハロゲン原子で置換されていても良い炭素数1〜4のアルキル、R3は水素原子;ハロゲン原子;シアノ;ハロゲン原子で置換されていても良い炭素数1〜4のアルキル;又はハロゲン原子で置換されていても良い炭素数2〜5のアシル、Ar3は置換されていても良いアリール、置換されていても良いヘテロアリール、保護されていても良い水酸基で置換されたフェニル又はベンジルオキシフェニル、Aは置換されていても良いアリーレン、置換されていても良いヘテロアリーレン又は単結合、Ra、Rbは水素原子又は保護基、Xcは脱離基、R2は水酸基で置換されていても良いか又はハロゲン原子で置換されていても良い炭素数1〜4のアルキル、Ar4は置換されていても良いアリール、置換されていても良いヘテロアリール、水酸基で置換されたフェニル又はベンジルオキシフェニルを示す。) - 一般式(II−1)で表される脱離基Xcを有するベンゼン化合物と一般式(II−2)で表されるベンゼンチオールとを縮合させることを特徴とする、一般式(II−3)で表される化合物の製造方法。
(式中、R8は保護されていても良い水酸基で置換されていても良いか又はハロゲン原子で置換されていても良い炭素数1〜4のアルキル、R3は水素原子;ハロゲン原子;シアノ;ハロゲン原子で置換されていても良い炭素数1〜4のアルキル;又はハロゲン原子で置換されていても良い炭素数2〜5のアシル、Ar3は置換されていても良いアリール、置換されていても良いヘテロアリール、保護されていても良い水酸基で置換されたフェニル又はベンジルオキシフェニル、Aは置換されていても良いアリーレン、置換されていても良いヘテロアリーレン又は単結合、Ra、Rbは水素原子又は保護基、Xcは脱離基を示す。) - 一般式(II−1’)で表されるチオール化合物と一般式(II−2’)で表される脱離基Xcを有するベンゼン化合物とを縮合させることを特徴とする、一般式(II−3)で表される化合物の製造方法。
(式中、R8は保護されていても良い水酸基で置換されていても良いか又はハロゲン原子で置換されていても良い炭素数1〜4のアルキル、R3は水素原子;ハロゲン原子;シアノ;ハロゲン原子で置換されていても良い炭素数1〜4のアルキル;又はハロゲン原子で置換されていても良い炭素数2〜5のアシル、Ar3は置換されていても良いアリール、置換されていても良いヘテロアリール、保護されていても良い水酸基で置換されたフェニル又はベンジルオキシフェニル、Aは置換されていても良いアリーレン、置換されていても良いヘテロアリーレン又は単結合、Ra、Rbは水素原子又は保護基、Xcは脱離基を示す。)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008513283A JP5100641B2 (ja) | 2006-04-28 | 2007-04-27 | 2−アミノブタノール化合物及びその医薬用途 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006126102 | 2006-04-28 | ||
JP2006126102 | 2006-04-28 | ||
JP2008513283A JP5100641B2 (ja) | 2006-04-28 | 2007-04-27 | 2−アミノブタノール化合物及びその医薬用途 |
PCT/JP2007/059150 WO2007126042A1 (ja) | 2006-04-28 | 2007-04-27 | 2-アミノブタノール化合物及びその医薬用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2007126042A1 true JPWO2007126042A1 (ja) | 2009-09-10 |
JP5100641B2 JP5100641B2 (ja) | 2012-12-19 |
Family
ID=38655563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008513283A Expired - Fee Related JP5100641B2 (ja) | 2006-04-28 | 2007-04-27 | 2−アミノブタノール化合物及びその医薬用途 |
Country Status (6)
Country | Link |
---|---|
US (1) | US8114902B2 (ja) |
EP (1) | EP2017257B1 (ja) |
JP (1) | JP5100641B2 (ja) |
ES (1) | ES2491224T3 (ja) |
TW (1) | TW200811083A (ja) |
WO (1) | WO2007126042A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2430925C2 (ru) | 2006-08-08 | 2011-10-10 | Киорин Фармасьютикал Ко., Лтд. | Производное аминофосфата и модулятор рецептора s1p, содержащий его в качестве активного ингредиента |
US8273748B2 (en) | 2006-08-08 | 2012-09-25 | Kyorin Pharmaceutical Co., Ltd. | Amino alcohol derivative and immunosuppresive agent having same as an active ingredient |
US8476305B2 (en) | 2008-02-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient |
BRPI0910236A2 (pt) * | 2008-03-24 | 2019-09-24 | Kyorin Seiyaku Kk | método para cristalização de composto |
AU2012242827A1 (en) * | 2011-04-14 | 2013-10-31 | Allergan, Inc. | Phenyl bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
CN104334556B (zh) | 2012-03-26 | 2017-05-17 | 爱若优生物科技有限公司 | 新型1‑磷酸鞘氨醇受体拮抗剂 |
ES2665336T3 (es) * | 2012-04-23 | 2018-04-25 | Mitsubishi Tanabe Pharma Corporation | Compuesto amina y su uso para propósitos médicos |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122011100012I1 (de) | 1992-10-21 | 2011-10-20 | Mitsubishi Tanabe Pharma Corp | 2-Amino-1, 3-propandiolverbindung und immunosuppressium. |
DE69524962T4 (de) | 1994-08-22 | 2003-08-28 | Mitsubishi Pharma Corp., Osaka | Benzolderivate und deren medizinische verwendung |
GB9707307D0 (en) | 1997-04-10 | 1997-05-28 | Ciba Geigy Ag | Polypeptide markers |
JP4152884B2 (ja) | 2001-09-27 | 2008-09-17 | 杏林製薬株式会社 | ジアリールエーテル誘導体とその付加塩及び免疫抑制剤 |
CN1329372C (zh) | 2001-09-27 | 2007-08-01 | 杏林制药株式会社 | 二芳基硫醚衍生物及其加成盐和免疫抑制剂 |
NZ536558A (en) * | 2002-05-27 | 2006-07-28 | Novartis Ag | Bis-aromatic alkanols |
JP2004307440A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | 2−アミノ‐1,3‐プロパンジオール誘導体とその付加塩 |
-
2007
- 2007-04-27 JP JP2008513283A patent/JP5100641B2/ja not_active Expired - Fee Related
- 2007-04-27 WO PCT/JP2007/059150 patent/WO2007126042A1/ja active Application Filing
- 2007-04-27 US US12/226,745 patent/US8114902B2/en not_active Expired - Fee Related
- 2007-04-27 ES ES07742585.8T patent/ES2491224T3/es active Active
- 2007-04-27 TW TW096114949A patent/TW200811083A/zh unknown
- 2007-04-27 EP EP07742585.8A patent/EP2017257B1/en not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
WO2007126042A1 (ja) | 2007-11-08 |
US8114902B2 (en) | 2012-02-14 |
EP2017257A1 (en) | 2009-01-21 |
EP2017257B1 (en) | 2014-08-06 |
ES2491224T3 (es) | 2014-09-05 |
US20090082311A1 (en) | 2009-03-26 |
EP2017257A4 (en) | 2010-04-14 |
TW200811083A (en) | 2008-03-01 |
JP5100641B2 (ja) | 2012-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5100641B2 (ja) | 2−アミノブタノール化合物及びその医薬用途 | |
TWI439263B (zh) | 胺化合物及其醫藥用途 | |
TWI451865B (zh) | 胺化合物及其醫藥用途 | |
JP4152884B2 (ja) | ジアリールエーテル誘導体とその付加塩及び免疫抑制剤 | |
JP4217620B2 (ja) | ジアリールスルフィド誘導体とその付加塩及び免疫抑制剤 | |
JP2022050538A (ja) | プロスタサイクリン(pgi2)受容体に関連する障害の処置に有用なpgi2受容体の調節因子 | |
ES2392167T3 (es) | Derivados aminopropanol como moduladores del receptor esfingosina-1-fosfato | |
WO2006129688A1 (ja) | 2-アミノブタノール化合物及びその医薬用途 | |
JP6194306B2 (ja) | アミン化合物及びその医薬用途 | |
JP2011136905A (ja) | ベンゼン化合物及びその医薬用途 | |
JP5021752B2 (ja) | 選択的trベータ1アゴニスト | |
JP2009057359A (ja) | アミンボランを用いる含フッ素アミン化合物の製造方法 | |
JP2006213599A (ja) | 2−アミノプロパン−1,3−ジオール化合物およびその医薬用途 | |
JP2007518681A (ja) | 環状ジアミン化合物及びこれを含有する医薬 | |
JPH0372067B2 (ja) | ||
WO1997034905A1 (en) | Phosphorus containing aryloxy and arylthiopropanol amine derivatives useful as beta adrenoreceptor agonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100310 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120626 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120822 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120911 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120925 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151005 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5100641 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |